Term,Overlap,P-value,Adjusted P-value,Old P-value,Old Adjusted P-value,Odds Ratio,Combined Score,Genes
ribosome biogenesis (GO:0042254),28/192,3.35E-22,5.09E-19,0,0,15.48599819,765.7301866,DDX27;NIP7;FCF1;NOLC1;NOL8;NOC4L;NOC2L;RPF2;SDAD1;WDR46;RRP9;EXOSC9;RRS1;UTP20;RIOK1;MDN1;PELP1;WDR36;UTP6;NOP16;WDR74;RRP1B;WDR12;UTP18;WDR55;BOP1;DHX29;NOL11
rRNA processing (GO:0006364),23/173,1.69E-17,1.29E-14,0,0,13.60295626,525.3077249,WDR36;UTP6;DDX27;FCF1;WDR74;NOLC1;NOL8;NOC4L;THUMPD1;RRP1B;WDR12;WDR46;UTP18;RRP9;WDR55;BOP1;ERI1;EXOSC9;UTP20;NOL11;RIOK1;MDN1;PELP1
rRNA metabolic process (GO:0016072),20/162,9.85E-15,4.99E-12,0,0,12.33274648,397.7439916,WDR36;UTP6;DDX27;FCF1;WDR74;NOLC1;NOL8;NOC4L;RRP1B;WDR12;WDR46;UTP18;RRP9;WDR55;BOP1;EXOSC9;UTP20;NOL11;MDN1;PELP1
ncRNA processing (GO:0034470),20/201,6.19E-13,2.35E-10,0,0,9.656176006,271.4477484,WDR36;UTP6;DDX27;FCF1;WDR74;NOLC1;NOL8;NOC4L;RRP1B;WDR12;WDR46;UTP18;RRP9;WDR55;BOP1;EXOSC9;UTP20;NOL11;MDN1;PELP1
ribosomal large subunit biogenesis (GO:0042273),11/57,8.00E-11,2.43E-08,0,0,20.22858742,470.2859568,BOP1;NOP16;NIP7;WDR74;RRS1;NOC2L;RPF2;SDAD1;WDR12;RSL24D1;MDN1
ribonucleoprotein complex biogenesis (GO:0022613),10/60,2.68E-09,6.79E-07,0,0,16.84273504,332.4138074,BOP1;NOP16;NIP7;WDR74;RRS1;RIOK1;NOC2L;RPF2;SDAD1;WDR12
"maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000466)",22-Jul,5.38E-09,1.17E-06,0,0,38.87116737,740.0959123,ERI1;EXOSC9;RRS1;UTP20;WDR12;NOP9;FTSJ3
ribonucleoprotein complex assembly (GO:0022618),12/136,1.11E-07,2.10E-05,0,0,8.189098999,131.1592409,PRMT5;BOP1;PRMT7;DDX23;RRS1;SMN1;DHX29;SNRNP200;RPF2;RSL24D1;MDN1;WDR77
protein localization to nucleolus (GO:1902570),06-Apr,3.18E-07,5.36E-05,0,0,164.6166667,2462.835879,PINX1;RRS1;NOL8;RPF2
"maturation of LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000463)",14-May,4.75E-07,7.21E-05,0,0,45.90190609,668.3566658,BOP1;ZNHIT6;RPF2;WDR12;FTSJ3
mRNA modification (GO:0016556),22-May,5.77E-06,7.81E-04,0,0,24.29116416,293.0397016,NSUN2;PUS1;TRMT6;PUS7;METTL16
spliceosomal snRNP assembly (GO:0000387),6/38,6.17E-06,7.81E-04,0,0,15.53886555,186.3959748,PRMT5;PRMT7;USP4;PRPF3;SMN1;WDR77
ribosomal large subunit assembly (GO:0000027),25-May,1.13E-05,0.001265566,0,0,20.64435146,235.1730539,BOP1;RRS1;RPF2;RSL24D1;MDN1
mitochondrial translational elongation (GO:0070125),8/89,1.32E-05,0.001265566,0,0,8.233940155,92.51405886,GADD45GIP1;MRPS25;MRPS18B;MRPS18A;MRPL15;MRPL35;CHCHD1;MRPL43
mitochondrial translational termination (GO:0070126),8/89,1.32E-05,0.001265566,0,0,8.233940155,92.51405886,GADD45GIP1;MRPS25;MRPS18B;MRPS18A;MRPL15;MRPL35;CHCHD1;MRPL43
maturation of LSU-rRNA (GO:0000470),26-May,1.38E-05,0.001265566,0,0,19.66029089,219.9598398,BOP1;ZNHIT6;RPF2;WDR12;FTSJ3
ribosomal subunit export from nucleus (GO:0000054),13-Apr,1.42E-05,0.001265566,0,0,36.56851852,408.2572183,RRS1;NMD3;SDAD1;NOP9
translational termination (GO:0006415),8/96,2.30E-05,0.001941719,0,0,7.576271186,80.90668905,GADD45GIP1;MRPS25;MRPS18B;MRPS18A;MRPL15;MRPL35;CHCHD1;MRPL43
"maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000462)",30-May,2.88E-05,0.002254424,0,0,16.51129707,172.6217345,UTP6;RRS1;UTP20;WDR46;NOP9
DNA-dependent DNA replication (GO:0006261),9/129,2.97E-05,0.002254424,0,0,6.266808511,65.32695169,POLE4;PSMD14;PSME3;PSMD3;ORC2;DDX23;POLD2;HMGA1;NOC3L
ribosome assembly (GO:0042255),6/50,3.14E-05,0.002272668,0,0,11.29411765,117.0909429,BOP1;RRS1;DHX29;RPF2;RSL24D1;MDN1
translational elongation (GO:0006414),8/104,4.11E-05,0.002838463,0,0,6.942090395,70.10538732,GADD45GIP1;MRPS25;MRPS18B;MRPS18A;MRPL15;CHCHD1;MRPL35;MRPL43
mitochondrial translation (GO:0032543),8/105,4.41E-05,0.002908434,0,0,6.870172986,68.90642904,GADD45GIP1;MRPS25;MRPS18B;MRPS18A;MRPL15;CHCHD1;MRPL35;MRPL43
ribosomal large subunit export from nucleus (GO:0000055),07-Mar,6.05E-05,0.003829441,0,0,61.46887967,596.993847,RRS1;NMD3;SDAD1
"endonucleolytic cleavage in ITS1 to separate SSU-rRNA from 5.8S rRNA and LSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000447)",08-Mar,9.60E-05,0.005604807,0,0,49.17261411,454.9048531,RRS1;UTP20;NOP9
leukocyte aggregation (GO:0070486),08-Mar,9.60E-05,0.005604807,0,0,49.17261411,454.9048531,IL1B;CD44;S100A8
protein methylation (GO:0006479),5/41,1.36E-04,0.007607682,0,0,11.45978615,102.0395353,PRMT5;PRMT7;PRMT3;FAM98B;FAM98A
tRNA modification (GO:0006400),6/65,1.40E-04,0.007607682,0,0,8.416322461,74.66575147,NSUN2;PUS1;TRMT6;TPRKB;THUMPD1;PUS7
"mRNA splicing, via spliceosome (GO:0000398)",12/274,1.46E-04,0.007630858,0,0,3.848512767,33.99548402,PRMT5;RBM17;PRMT7;PRPF3;DDX23;SNRNP48;SMN1;DDX41;GTF2F1;SNRNP200;GTF2F2;WDR77
pseudouridine synthesis (GO:0001522),13-Mar,4.69E-04,0.022946594,0,0,24.58008299,188.4247103,PUS1;GAR1;PUS7
"endonucleolytic cleavage of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000479)",13-Mar,4.69E-04,0.022946594,0,0,24.58008299,188.4247103,RRS1;UTP20;NOP9
"regulation of gene expression, epigenetic (GO:0040029)",6/82,5.01E-04,0.023757237,0,0,6.528084918,49.60875264,PRMT7;AEBP2;MYBBP1A;SMYD5;POLR1B;POLR1E
nucleoside triphosphate metabolic process (GO:0009141),14-Mar,5.91E-04,0.02718826,0,0,22.34439834,166.0995748,NME2;DCTPP1;ITPA
RNA modification (GO:0009451),5/58,7.02E-04,0.031337896,0,0,7.777295334,56.47650689,NSUN2;TRMT6;THUMPD1;PUS7;FTSJ3
mRNA methylation (GO:0080009),15-Mar,7.32E-04,0.031755549,0,0,20.4813278,147.8647147,NSUN2;TRMT6;METTL16
maturation of SSU-rRNA (GO:0030490),4/35,8.41E-04,0.035450872,0,0,10.60483871,75.09538106,UTP6;RIOK1;NOL11;WDR46
regulation of stem cell differentiation (GO:2000736),6/91,8.71E-04,0.035714649,0,0,5.834206624,41.11030171,PSMD14;SMYD5;NSUN2;PSME3;PSMD3;PUS7
rRNA transcription (GO:0009303),18-Mar,0.001278071,0.050565435,0,0,16.38257261,109.1473021,GTF3C5;GTF3C6;POLR1E
translation (GO:0006412),9/214,0.001299112,0.050565435,0,0,3.652496108,24.27476068,AIMP2;COPS5;PPA1;PABPC4;MRPS18B;MRPS18A;MRPL35;RSL24D1;MRPL43
nucleoside triphosphate catabolic process (GO:0009143),05-Feb,0.00144679,0.051075054,0,0,54.41597796,355.7938614,DCTPP1;ITPA
"endonucleolytic cleavage in 5'-ETS of tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000480)",05-Feb,0.00144679,0.051075054,0,0,54.41597796,355.7938614,UTP20;NOP9
"endonucleolytic cleavage to generate mature 5'-end of SSU-rRNA from (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000472)",05-Feb,0.00144679,0.051075054,0,0,54.41597796,355.7938614,UTP20;NOP9
rRNA 5'-end processing (GO:0000967),05-Feb,0.00144679,0.051075054,0,0,54.41597796,355.7938614,UTP20;NOP9
"transcription, DNA-templated (GO:0006351)",9/221,0.001622092,0.055962164,0,0,3.530630269,22.68090576,PRMT5;GTF3C5;GTF3C6;POLR3G;SMN1;MED4;GTF2F1;PWP1;GTF2F2
positive regulation of cellular process (GO:0048522),17/625,0.001801925,0.06078495,0,0,2.358538141,14.90336552,MTPN;CSF1;HMGA2;PHB;DNPH1;CXCL5;WDR77;FOSL1;PAK1;CSPP1;IL1B;EXOSC9;FAM98B;TIMP1;P4HB;FAM98A;S100A8
rRNA modification (GO:0000154),21-Mar,0.002027672,0.066913162,0,0,13.65006916,84.64226541,GAR1;THUMPD1;FTSJ3
5S class rRNA transcription by RNA polymerase III (GO:0042791),06-Feb,0.002152734,0.068080203,0,0,40.80991736,250.6143866,GTF3C5;GTF3C6
tRNA pseudouridine synthesis (GO:0031119),06-Feb,0.002152734,0.068080203,0,0,40.80991736,250.6143866,PUS1;PUS7
posttranscriptional regulation of gene expression (GO:0010608),4/46,0.002359828,0.073106505,0,0,7.823015873,47.32272626,MTPN;NOLC1;METTL16;PUM3
positive regulation of transcription by RNA polymerase I (GO:0045943),23-Mar,0.002651938,0.075993921,0,0,12.28381743,72.87330978,DHX33;NOL11;PWP1
protein alkylation (GO:0008213),23-Mar,0.002651938,0.075993921,0,0,12.28381743,72.87330978,PRMT3;FAM98B;FAM98A
base-excision repair (GO:0006284),4/48,0.002760927,0.075993921,0,0,7.466666667,43.9950101,APEX1;POLD2;HMGA2;LIG3
regulation of protein metabolic process (GO:0051246),4/48,0.002760927,0.075993921,0,0,7.466666667,43.9950101,MTPN;TRAF3;PLAUR;GSAP
regulation of cellular protein metabolic process (GO:0032268),4/49,0.002977963,0.075993921,0,0,7.30037037,42.46271942,MTPN;CSF1;NOLC1;PUM3
regulation of atrial cardiac muscle cell membrane repolarization (GO:0060372),07-Feb,0.002989614,0.075993921,0,0,32.64628099,189.7601315,FLNA;SCN5A
positive regulation of humoral immune response (GO:0002922),07-Feb,0.002989614,0.075993921,0,0,32.64628099,189.7601315,IL1B;PHB
tRNA transcription by RNA polymerase III (GO:0042797),07-Feb,0.002989614,0.075993921,0,0,32.64628099,189.7601315,GTF3C5;GTF3C6
mRNA pseudouridine synthesis (GO:1990481),07-Feb,0.002989614,0.075993921,0,0,32.64628099,189.7601315,PUS1;PUS7
purine nucleotide metabolic process (GO:0006163),24-Mar,0.003003712,0.075993921,0,0,11.69828097,67.94252004,PRPS1;DNPH1;ITPA
heterochromatin assembly (GO:0031507),24-Mar,0.003003712,0.075993921,0,0,11.69828097,67.94252004,HMGA1;HMGA2;RRP8
regulation of intrinsic apoptotic signaling pathway (GO:2001242),4/52,0.00369844,0.089588228,0,0,6.843055556,38.3200447,PLAUR;P4HB;NOC2L;S100A8
histone methylation (GO:0016571),26-Mar,0.003789955,0.089588228,0,0,10.6799567,59.54504194,PRMT5;PRMT7;SMYD2
peptide biosynthetic process (GO:0043043),7/162,0.003802958,0.089588228,0,0,3.735048319,20.81159999,COPS5;PABPC4;MRPS18B;MRPS18A;RSL24D1;MRPL35;MRPL43
box C/D snoRNP assembly (GO:0000492),08-Feb,0.003954158,0.089588228,0,0,27.20385675,150.5186046,RUVBL2;ZNHIT6
regulation of protein localization to nucleolus (GO:1904749),08-Feb,0.003954158,0.089588228,0,0,27.20385675,150.5186046,PINX1;NMD3
regulation of RNA biosynthetic process (GO:2001141),08-Feb,0.003954158,0.089588228,0,0,27.20385675,150.5186046,IL1B;NMD3
tRNA transcription (GO:0009304),08-Feb,0.003954158,0.089588228,0,0,27.20385675,150.5186046,GTF3C5;GTF3C6
nucleobase-containing small molecule interconversion (GO:0015949),27-Mar,0.00422568,0.093265667,0,0,10.23443983,55.94733421,NME2;NME4;AK6
regulation of proteolysis (GO:0030162),4/54,0.004239348,0.093265667,0,0,6.568666667,35.88689667,DNAJC1;TRAF3;PLAUR;GSAP
transcription by RNA polymerase III (GO:0006383),28-Mar,0.004690584,0.101718672,0,0,9.824564315,52.68126016,GTF3C5;GTF3C6;POLR3G
peptidyl-cysteine modification (GO:0018198),09-Feb,0.005043151,0.102804436,0,0,23.31641086,123.3373842,CHCHD4;S100A8
exonucleolytic trimming involved in rRNA processing (GO:0000459),09-Feb,0.005043151,0.102804436,0,0,23.31641086,123.3373842,ERI1;EXOSC9
"exonucleolytic trimming to generate mature 3'-end of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000467)",09-Feb,0.005043151,0.102804436,0,0,23.31641086,123.3373842,ERI1;EXOSC9
histone arginine methylation (GO:0034969),09-Feb,0.005043151,0.102804436,0,0,23.31641086,123.3373842,PRMT5;PRMT7
negative regulation of cell cycle G2/M phase transition (GO:1902750),4/57,0.005146994,0.102804436,0,0,6.19591195,32.64838152,PSMD14;PSME3;PINX1;PSMD3
"positive regulation of gene expression, epigenetic (GO:0045815)",4/57,0.005146994,0.102804436,0,0,6.19591195,32.64838152,MYBBP1A;POLR1B;HMGA1;POLR1E
cellular macromolecule biosynthetic process (GO:0034645),10/314,0.005380805,0.106078724,0,0,2.734480432,14.28743415,COPS5;PABPC4;ORC2;POLD2;MRPS18B;MRPS18A;PWP1;MRPL35;RSL24D1;MRPL43
positive regulation of cell population proliferation (GO:0008284),13/474,0.005671898,0.110383862,0,0,2.355457269,12.18297019,CSF1;NME2;HMGA2;PHB;CXCL5;WDR77;FOSL1;PAK1;IL1B;FAM98B;TIMP1;SCN5A;FAM98A
RNA methylation (GO:0001510),4/60,0.006176385,0.114370113,0,0,5.863095238,29.82569477,NSUN2;TRMT6;METTL16;FTSJ3
regulation of microtubule nucleation (GO:0010968),10-Feb,0.006253438,0.114370113,0,0,20.40082645,103.5265201,PAK1;RANGRF
rRNA 3'-end processing (GO:0031125),10-Feb,0.006253438,0.114370113,0,0,20.40082645,103.5265201,ERI1;EXOSC9
small nucleolar ribonucleoprotein complex assembly (GO:0000491),10-Feb,0.006253438,0.114370113,0,0,20.40082645,103.5265201,RUVBL2;ZNHIT6
positive regulation of transcription of nucleolar large rRNA by RNA polymerase I (GO:1901838),10-Feb,0.006253438,0.114370113,0,0,20.40082645,103.5265201,NOL11;PWP1
regulation of cellular amide metabolic process (GO:0034248),3/32,0.006852323,0.123831265,0,0,8.467735012,42.19614249,MTPN;NOLC1;PUM3
regulation of histone acetylation (GO:0035065),3/33,0.007470587,0.133415899,0,0,8.185062241,40.08046275,RUVBL2;IL1B;NOC2L
regulation of intracellular signal transduction (GO:1902531),12/437,0.007661315,0.133682872,0,0,2.352657201,11.461138,PRMT5;BOP1;PAK1;TRAF3;PRKAR2A;IL1B;RRS1;ARHGDIG;SMYD2;NOC2L;RPF2;ITFG2
tRNA processing (GO:0008033),4/64,0.007749732,0.133682872,0,0,5.471111111,26.59013098,NSUN2;TRMT6;FAM98B;THUMPD1
pre-replicative complex assembly (GO:0036388),4/64,0.007749732,0.133682872,0,0,5.471111111,26.59013098,PSMD14;PSME3;PSMD3;ORC2
positive regulation of vasculature development (GO:1904018),5/102,0.008286856,0.141342112,0,0,4.239960316,20.32248846,IL1B;ADAM12;HMGA2;ANGPTL4;HK2
negative regulation of G2/M transition of mitotic cell cycle (GO:0010972),4/66,0.00862663,0.145502485,0,0,5.294086022,25.16226888,PSMD14;PSME3;PINX1;PSMD3
"base-excision repair, gap-filling (GO:0006287)",3/35,0.008803304,0.146850718,0,0,7.672717842,36.31212068,APEX1;POLD2;LIG3
positive regulation of cellular senescence (GO:2000774),12-Feb,0.009025566,0.14888285,0,0,16.31900826,76.82489757,HMGA1;HMGA2
regulation of mRNA stability (GO:0043488),6/146,0.009121281,0.14888285,0,0,3.532292917,16.59169198,PSMD14;PSME3;EXOSC9;APEX1;PSMD3;METTL16
protein localization to nucleus (GO:0034504),5/106,0.00969752,0.156604629,0,0,4.071212561,18.8736737,PINX1;RRS1;NOL8;RPF2;TNPO3
neutrophil chemotaxis (GO:0030593),4/70,0.010569461,0.160625391,0,0,4.972222222,22.62254923,CXCL3;CXCL2;CXCL5;S100A8
"DNA-templated transcription, termination (GO:0006353)",4/70,0.010569461,0.160625391,0,0,4.972222222,22.62254923,PRMT5;POLR1B;POLR1E;SMN1
purine nucleotide catabolic process (GO:0006195),13-Feb,0.010581383,0.160625391,0,0,14.83471074,67.47804294,DNPH1;ITPA
purine-containing compound catabolic process (GO:0072523),13-Feb,0.010581383,0.160625391,0,0,14.83471074,67.47804294,DNPH1;ITPA
positive regulation of cell aging (GO:0090343),13-Feb,0.010581383,0.160625391,0,0,14.83471074,67.47804294,HMGA1;HMGA2
spliceosomal tri-snRNP complex assembly (GO:0000244),13-Feb,0.010581383,0.160625391,0,0,14.83471074,67.47804294,USP4;PRPF3
DNA replication initiation (GO:0006270),3/38,0.011047759,0.165130435,0,0,7.01398933,31.60172297,POLE4;ORC2;NOC3L
regulation of hematopoietic stem cell differentiation (GO:1902036),4/71,0.011095721,0.165130435,0,0,4.897761194,22.04578186,PSMD14;PSME3;PSMD3;PUS7
Fc-epsilon receptor signaling pathway (GO:0038095),5/111,0.011682481,0.170551393,0,0,3.878187416,17.25663443,PAK1;PSMD14;PSME3;PSMD3;NFATC1
Fc receptor signaling pathway (GO:0038093),5/112,0.012110208,0.170551393,0,0,3.841747155,16.95634453,PAK1;PSMD14;PSME3;PSMD3;NFATC1
"RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377)",8/251,0.012184507,0.170551393,0,0,2.722047848,11.99767107,RBM17;PRPF3;DDX23;SNRNP48;DDX41;GTF2F1;SNRNP200;GTF2F2
granulocyte chemotaxis (GO:0071621),4/73,0.012198221,0.170551393,0,0,4.75531401,20.9541255,CXCL3;CXCL2;CXCL5;S100A8
regulation of integrin-mediated signaling pathway (GO:2001044),14-Feb,0.012246444,0.170551393,0,0,13.59779614,59.86456507,FLNA;TIMP1
nucleoside phosphate catabolic process (GO:1901292),14-Feb,0.012246444,0.170551393,0,0,13.59779614,59.86456507,DCTPP1;ITPA
regulation of transcription of nucleolar large rRNA by RNA polymerase I (GO:1901836),14-Feb,0.012246444,0.170551393,0,0,13.59779614,59.86456507,NOL11;PWP1
regulation of signal transduction by p53 class mediator (GO:1901796),6/156,0.012371399,0.170725306,0,0,3.29512605,14.47340624,PRMT5;BOP1;RRS1;SMYD2;NOC2L;RPF2
regulation of hematopoietic progenitor cell differentiation (GO:1901532),4/75,0.013368538,0.182823786,0,0,4.620892019,19.93846178,PSMD14;PSME3;PSMD3;PUS7
cellular protein metabolic process (GO:0044267),11/417,0.013781912,0.183440815,0,0,2.25004757,9.640099981,COPS5;CSF1;PABPC4;MRPS18B;TNC;MRPS18A;TIMP1;P4HB;MRPL35;RSL24D1;MRPL43
positive regulation of angiogenesis (GO:0045766),5/116,0.01392733,0.183440815,0,0,3.702551924,15.82434477,IL1B;ADAM12;HMGA2;ANGPTL4;HK2
positive regulation of growth (GO:0045927),4/76,0.013979548,0.183440815,0,0,4.556481481,19.45690454,MTPN;EXOSC9;DNPH1;S100A8
peptidyl-arginine modification (GO:0018195),15-Feb,0.014017875,0.183440815,0,0,12.5511761,53.56116455,PRMT5;PRMT7
positive regulation of heterotypic cell-cell adhesion (GO:0034116),15-Feb,0.014017875,0.183440815,0,0,12.5511761,53.56116455,IL1B;CD44
negative regulation of protein catabolic process (GO:0042177),3/42,0.014509383,0.187923317,0,0,6.293329078,26.63940848,FLNA;PHB;TIMP1
neutrophil migration (GO:1990266),4/77,0.014608005,0.187923317,0,0,4.493835616,18.99178345,CXCL3;CXCL2;CXCL5;S100A8
cellular response to glucose starvation (GO:0042149),3/43,0.015459872,0.1972108,0,0,6.135684647,25.58278338,MYBBP1A;ITFG2;RRP8
nucleotide catabolic process (GO:0009166),16-Feb,0.015892855,0.197748807,0,0,11.6540732,48.26983817,DNPH1;ITPA
epiboly involved in wound healing (GO:0090505),16-Feb,0.015892855,0.197748807,0,0,11.6540732,48.26983817,FLNA;CD44
"mRNA cis splicing, via spliceosome (GO:0045292)",16-Feb,0.015892855,0.197748807,0,0,11.6540732,48.26983817,DDX23;SNRNP200
regulation of mRNA catabolic process (GO:0061013),5/122,0.016983333,0.209599185,0,0,3.51160462,14.31162476,PSMD14;PSME3;EXOSC9;APEX1;PSMD3
positive regulation of RNA metabolic process (GO:0051254),3/45,0.01746394,0.213792429,0,0,5.84291642,23.64988833,IL1B;NMD3;RIOK1
maturation of 5.8S rRNA (GO:0000460),17-Feb,0.017868616,0.21699647,0,0,10.87658402,43.77509009,WDR12;FTSJ3
spliceosomal complex assembly (GO:0000245),3/46,0.018517718,0.223094409,0,0,5.706745151,22.76436213,DDX23;SMN1;SNRNP200
negative regulation of programmed cell death (GO:0043069),10/381,0.018997176,0.227068608,0,0,2.23293478,8.850158716,COPS5;HAX1;NME2;PLAUR;FLNA;HMGA2;WDR73;ANGPTL4;MET;CD44
positive regulation of cell-cell adhesion (GO:0022409),3/47,0.019606089,0.231088725,0,0,5.576763485,21.92736062,IL1B;PLAUR;CD44
regulation of membrane depolarization (GO:0003254),18-Feb,0.019942439,0.231088725,0,0,10.19628099,39.91747333,RANGRF;SCN5A
DNA strand elongation involved in DNA replication (GO:0006271),18-Feb,0.019942439,0.231088725,0,0,10.19628099,39.91747333,POLD2;LIG3
regulation of transcription by RNA polymerase I (GO:0006356),18-Feb,0.019942439,0.231088725,0,0,10.19628099,39.91747333,DHX33;FLNA
establishment of protein localization to mitochondrion (GO:0072655),3/48,0.020729102,0.237168196,0,0,5.452558783,21.13529929,CHCHD4;TIMM23;HK2
DNA metabolic process (GO:0006259),8/277,0.020779559,0.237168196,0,0,2.455673871,9.512753907,POLE4;APEX1;ORC2;DDX23;POLD2;LIG3;NOC3L;DCTPP1
negative regulation of catabolic process (GO:0009895),3/49,0.021886787,0.246805145,0,0,5.333754285,20.38492694,IL1B;FLNA;PHB
regulation of autophagy of mitochondrion (GO:1903146),19-Feb,0.02211166,0.246805145,0,0,9.596013612,36.57664732,HAX1;CAMKK2
positive regulation of G protein-coupled receptor signaling pathway (GO:0045745),19-Feb,0.02211166,0.246805145,0,0,9.596013612,36.57664732,PRMT5;PHB
regulation of type I interferon production (GO:0032479),4/89,0.023560578,0.258735787,0,0,3.857058824,14.45695228,DHX33;TRAF3;POLR3G;DDX41
SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146),4/89,0.023560578,0.258735787,0,0,3.857058824,14.45695228,PSMD14;PSME3;PSMD3;FBXO17
regulation of cellular amine metabolic process (GO:0033238),3/51,0.024306204,0.258735787,0,0,5.110995851,18.99769252,PSMD14;PSME3;PSMD3
negative regulation of protein ubiquitination (GO:0031397),3/51,0.024306204,0.258735787,0,0,5.110995851,18.99769252,USP4;PINX1;PRMT3
mitotic metaphase plate congression (GO:0007080),3/51,0.024306204,0.258735787,0,0,5.110995851,18.99769252,EML4;PINX1;RRS1
hepaticobiliary system development (GO:0061008),20-Feb,0.024373661,0.258735787,0,0,9.062442608,33.66019733,GFER;MET
positive regulation of peptidyl-lysine acetylation (GO:2000758),20-Feb,0.024373661,0.258735787,0,0,9.062442608,33.66019733,IL1B;RUVBL2
negative regulation of mitotic cell cycle phase transition (GO:1901991),4/92,0.026219505,0.272281072,0,0,3.725,13.56366247,PSMD14;PSME3;PINX1;PSMD3
cellular response to fibroblast growth factor stimulus (GO:0044344),4/92,0.026219505,0.272281072,0,0,3.725,13.56366247,FLRT2;GTF2F1;GTF2F2;CD44
post-translational protein modification (GO:0043687),9/345,0.026250129,0.272281072,0,0,2.213525836,8.057420806,COPS5;CSF1;PSMD14;PSME3;PSMD3;FBXO17;TNC;TIMP1;P4HB
negative regulation of reproductive process (GO:2000242),21-Feb,0.026725876,0.272281072,0,0,8.585036973,31.09606027,TIMP1;WDR77
focal adhesion assembly (GO:0048041),21-Feb,0.026725876,0.272281072,0,0,8.585036973,31.09606027,PEAK1;ACTN1
mitochondrial calcium ion transmembrane transport (GO:0006851),21-Feb,0.026725876,0.272281072,0,0,8.585036973,31.09606027,PMPCA;PHB
interleukin-1-mediated signaling pathway (GO:0070498),4/94,0.028088183,0.283444789,0,0,3.641851852,13.01017465,PSMD14;IL1B;PSME3;PSMD3
regulation of cellular amino acid metabolic process (GO:0006521),3/54,0.028195101,0.283444789,0,0,4.809616793,17.16363236,PSMD14;PSME3;PSMD3
regulation of cardiac muscle cell membrane repolarization (GO:0099623),22-Feb,0.029165786,0.285636534,0,0,8.155371901,28.82727405,FLNA;SCN5A
regulation of membrane protein ectodomain proteolysis (GO:0051043),22-Feb,0.029165786,0.285636534,0,0,8.155371901,28.82727405,IL1B;TIMP1
"positive regulation of DNA-templated transcription, initiation (GO:2000144)",22-Feb,0.029165786,0.285636534,0,0,8.155371901,28.82727405,FOSL1;MED4
rRNA methylation (GO:0031167),22-Feb,0.029165786,0.285636534,0,0,8.155371901,28.82727405,METTL16;FTSJ3
protein targeting to mitochondrion (GO:0006626),3/55,0.029560467,0.285813943,0,0,4.716884775,16.60964835,CHCHD4;TIMM23;PMPCA
negative regulation of protein modification by small protein conjugation or removal (GO:1903321),3/55,0.029560467,0.285813943,0,0,4.716884775,16.60964835,USP4;PINX1;PRMT3
chemokine-mediated signaling pathway (GO:0070098),3/56,0.030960236,0.293334241,0,0,4.627652079,16.08132979,CXCL3;CXCL2;CXCL5
telomere maintenance (GO:0000723),3/56,0.030960236,0.293334241,0,0,4.627652079,16.08132979,APEX1;POLD2;TPRKB
gene expression (GO:0010467),9/356,0.031206234,0.293334241,0,0,2.142142375,7.427101938,COPS5;PABPC4;MRPS18B;MRPS18A;PWP1;MRPL35;RSL24D1;MRPL43;AGFG1
mRNA processing (GO:0006397),8/300,0.03138295,0.293334241,0,0,2.259577432,7.82150588,RBM17;PRPF3;DDX23;SNRNP48;DDX41;GTF2F1;SNRNP200;GTF2F2
nucleotide metabolic process (GO:0009117),23-Feb,0.031690919,0.293334241,0,0,7.766627312,26.8082624,NME2;NUDT5
positive regulation of histone acetylation (GO:0035066),23-Feb,0.031690919,0.293334241,0,0,7.766627312,26.8082624,IL1B;RUVBL2
hyaluronan metabolic process (GO:0030212),23-Feb,0.031690919,0.293334241,0,0,7.766627312,26.8082624,IL1B;CD44
cell-matrix adhesion (GO:0007160),4/100,0.034160535,0.309914631,0,0,3.413194444,11.52527992,PEAK1;ACTN1;ITGA7;CD44
"nucleotide-excision repair, DNA gap filling (GO:0006297)",24-Feb,0.034298852,0.309914631,0,0,7.41322314,25.00215795,POLD2;LIG3
"wound healing, spreading of cells (GO:0044319)",24-Feb,0.034298852,0.309914631,0,0,7.41322314,25.00215795,FLNA;CD44
protein exit from endoplasmic reticulum (GO:0032527),24-Feb,0.034298852,0.309914631,0,0,7.41322314,25.00215795,SURF4;RANGRF
positive regulation of cell growth (GO:0030307),4/102,0.036341235,0.322681495,0,0,3.343197279,11.08203781,MTPN;EXOSC9;DNPH1;S100A8
cellular response to chemokine (GO:1990869),3/60,0.036901126,0.322681495,0,0,4.302031011,14.19460818,CXCL3;CXCL2;CXCL5
regulation of heterotypic cell-cell adhesion (GO:0034114),25-Feb,0.036987207,0.322681495,0,0,7.090549766,23.37884146,IL1B;CD44
regulation of proteolysis involved in cellular protein catabolic process (GO:1903050),25-Feb,0.036987207,0.322681495,0,0,7.090549766,23.37884146,PSMD14;PSME3
glycolytic process through glucose-6-phosphate (GO:0061620),25-Feb,0.036987207,0.322681495,0,0,7.090549766,23.37884146,ADPGK;HK2
"RNA splicing, via transesterification reactions (GO:0000375)",25-Feb,0.036987207,0.322681495,0,0,7.090549766,23.37884146,PRPF3;DDX23
chromatin remodeling (GO:0006338),4/103,0.037461075,0.324948066,0,0,3.309259259,10.86910614,PAK1;RUVBL2;HMGA2;NUDT5
positive regulation of microtubule polymerization or depolymerization (GO:0031112),26-Feb,0.03975365,0.333728565,0,0,6.79476584,21.91348422,PAK1;MET
positive regulation of viral transcription (GO:0050434),26-Feb,0.03975365,0.333728565,0,0,6.79476584,21.91348422,GTF2F1;GTF2F2
cytokine-mediated signaling pathway (GO:0019221),13/621,0.041866092,0.333728565,0,0,1.772357029,5.624183398,CSF1;PSMD14;GSTO1;CXCL3;CXCL2;CXCL5;TRAF3;PSME3;IL1B;PSMD3;TIMP1;P4HB;CD44
regulation of cardiac muscle cell contraction (GO:0086004),27-Feb,0.042595892,0.333728565,0,0,6.522644628,20.58544986,RANGRF;SCN5A
cellular senescence (GO:0090398),27-Feb,0.042595892,0.333728565,0,0,6.522644628,20.58544986,HMGA1;HMGA2
antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844),3/64,0.043382035,0.333728565,0,0,4.019114346,12.61081474,CXCL3;CXCL2;CXCL5
regulation of cellular ketone metabolic process (GO:0010565),3/64,0.043382035,0.333728565,0,0,4.019114346,12.61081474,PSMD14;PSME3;PSMD3
regulation of protein ubiquitination (GO:0031396),4/109,0.04459366,0.333728565,0,0,3.119206349,9.701241993,USP4;PINX1;PRMT3;HSPBP1
T cell receptor signaling pathway (GO:0050852),5/158,0.04461135,0.333728565,0,0,2.680422239,8.335488554,EIF2B5;PAK1;PSMD14;PSME3;PSMD3
"regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043516)",28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,SMYD2;CD44
regulation of protein transport (GO:0051223),28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,DNAJC1;GAPVD1
regulation of sodium ion transmembrane transport (GO:1902305),28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,RANGRF;SCN5A
positive regulation of microtubule polymerization (GO:0031116),28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,PAK1;MET
positive regulation of monooxygenase activity (GO:0032770),28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,NUS1;IL1B
protein localization to cell surface (GO:0034394),28-Feb,0.04551169,0.333728565,0,0,6.271455817,19.37745677,USP4;FLNA
response to lipopolysaccharide (GO:0032496),5/159,0.045621874,0.333728565,0,0,2.662881052,8.221293688,IL1B;CXCL3;CXCL2;S100A8;CXCL5
protein deubiquitination (GO:0016579),7/267,0.045959179,0.333728565,0,0,2.214735475,6.821389027,USP24;COPS5;PSMD14;USP4;TRAF3;PSME3;PSMD3
regulation of cell population proliferation (GO:0042127),15/764,0.048275299,0.333728565,0,0,1.662216288,5.03790373,CSF1;PINX1;CDCA7;HMGA1;PHB;CXCL5;WDR77;FOSL1;PAK1;IL1B;SMYD2;UTP20;FAM98B;TIMP1;FAM98A
telomere maintenance via telomerase (GO:0007004),2/29,0.048498842,0.333728565,0,0,6.038873584,18.27493203,PINX1;GAR1
sulfur compound biosynthetic process (GO:0044272),4/113,0.049742262,0.333728565,0,0,3.00412844,9.015090155,CHPF;GSTO1;METTL16;CNDP2
positive regulation of protein localization to nucleus (GO:1900182),3/68,0.05039133,0.333728565,0,0,3.771018193,11.26756159,PINX1;FLNA;NMD3
"negative regulation of gene expression, epigenetic (GO:0045814)",2/30,0.051555188,0.333728565,0,0,5.822904368,17.26550794,AEBP2;SMYD5
regulation of cation transmembrane transport (GO:1904062),2/30,0.051555188,0.333728565,0,0,5.822904368,17.26550794,RANGRF;SCN5A
RNA-dependent DNA biosynthetic process (GO:0006278),2/30,0.051555188,0.333728565,0,0,5.822904368,17.26550794,PINX1;GAR1
termination of RNA polymerase I transcription (GO:0006363),2/30,0.051555188,0.333728565,0,0,5.822904368,17.26550794,POLR1B;POLR1E
"DNA-templated transcription, elongation (GO:0006354)",3/69,0.052224591,0.333728565,0,0,3.713692946,10.96357098,POLR1E;GTF2F1;GTF2F2
cellular response to lectin (GO:1990858),4/115,0.052434176,0.333728565,0,0,2.9496997,8.69629488,PAK1;PSMD14;PSME3;PSMD3
cellular response to molecule of bacterial origin (GO:0071219),4/115,0.052434176,0.333728565,0,0,2.9496997,8.69629488,IL1B;CXCL3;CXCL2;CXCL5
stimulatory C-type lectin receptor signaling pathway (GO:0002223),4/115,0.052434176,0.333728565,0,0,2.9496997,8.69629488,PAK1;PSMD14;PSME3;PSMD3
protein modification by small protein removal (GO:0070646),7/276,0.053140332,0.333728565,0,0,2.13964833,6.279480775,USP24;COPS5;PSMD14;USP4;TRAF3;PSME3;PSMD3
tumor necrosis factor-mediated signaling pathway (GO:0033209),4/116,0.053809422,0.333728565,0,0,2.923214286,8.542528686,PSMD14;TRAF3;PSME3;PSMD3
positive regulation of cell-substrate adhesion (GO:0010811),3/70,0.054089749,0.333728565,0,0,3.6580789,10.67102073,CSF1;FLNA;P4HB
regulation of cellular senescence (GO:2000772),2/31,0.054678611,0.333728565,0,0,5.621829581,16.33862589,HMGA1;HMGA2
nucleic acid metabolic process (GO:0090304),3/71,0.055986546,0.333728565,0,0,3.604100561,10.38933836,WDR74;GTF2F1;GTF2F2
7-methylguanosine mRNA capping (GO:0006370),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,GTF2F1;GTF2F2
7-methylguanosine RNA capping (GO:0009452),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,GTF2F1;GTF2F2
protein transmembrane import into intracellular organelle (GO:0044743),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,CHCHD4;TIMM23
endodermal cell differentiation (GO:0035987),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,HMGA2;ITGA7
positive regulation of immune effector process (GO:0002699),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,IL1B;PHB
RNA biosynthetic process (GO:0032774),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,PRMT5;SMN1
liver development (GO:0001889),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,GFER;MET
transcription initiation from RNA polymerase I promoter (GO:0006361),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,POLR1B;POLR1E
modulation by host of symbiont process (GO:0051851),2/32,0.057867035,0.333728565,0,0,5.43415978,15.48522195,HMGA2;RRP1B
innate immune response activating cell surface receptor signaling pathway (GO:0002220),4/119,0.058051798,0.333728565,0,0,2.846521739,8.102395257,PAK1;PSMD14;PSME3;PSMD3
cellular response to lipopolysaccharide (GO:0071222),4/120,0.059504636,0.333728565,0,0,2.82183908,7.962386292,IL1B;CXCL3;CXCL2;CXCL5
5-phosphoribose 1-diphosphate biosynthetic process (GO:0006015),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PRPS1
5-phosphoribose 1-diphosphate metabolic process (GO:0046391),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PRPS1
protein processing involved in protein targeting to mitochondrion (GO:0006627),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PMPCA
activation of protein kinase C activity (GO:1990051),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PHB
pyrimidine nucleotide metabolic process (GO:0006220),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PRPS1
R-loop disassembly (GO:0062176),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,DDX23
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway (GO:2001268),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PLAUR
regulation of barbed-end actin filament capping (GO:2000812),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,MTPN
bundle of His cell action potential (GO:0086043),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
negative regulation of metallopeptidase activity (GO:1905049),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,TIMP1
regulation of fever generation (GO:0031620),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
regulation of guanyl-nucleotide exchange factor activity (GO:1905097),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,MET
negative regulation of transcription by RNA polymerase I (GO:0016479),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,FLNA
regulation of intracellular cholesterol transport (GO:0032383),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,NUS1
regulation of mononuclear cell proliferation (GO:0032944),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,CSF1
pentose catabolic process (GO:0019323),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,NUDT5
peptidyl-cysteine S-nitrosylation (GO:0018119),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,S100A8
DNA ligation involved in DNA repair (GO:0051103),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,LIG3
DNA protection (GO:0042262),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,DCTPP1
regulation of platelet-derived growth factor receptor-beta signaling pathway (GO:2000586),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PTPN12
positive regulation of action potential (GO:0045760),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
positive regulation of anoikis (GO:2000210),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,MYBBP1A
extracellular exosome biogenesis (GO:0097734),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,COPS5
regulation of T-helper 1 cell cytokine production (GO:2000554),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
positive regulation of dopamine receptor signaling pathway (GO:0060161),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,PRMT5
positive regulation of glial cell proliferation (GO:0060252),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
response to denervation involved in regulation of muscle adaptation (GO:0014894),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
positive regulation of heat generation (GO:0031652),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
histone H4-K20 methylation (GO:0034770),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SMYD5
histone H4-K20 trimethylation (GO:0034773),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SMYD5
ribose phosphate metabolic process (GO:0019693),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,NUDT5
SA node cell to atrial cardiac muscle cell signaling (GO:0086018),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
positive regulation of mononuclear cell proliferation (GO:0032946),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,CSF1
spliceosomal conformational changes to generate catalytic conformation (GO:0000393),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SNRNP200
positive regulation of prostaglandin biosynthetic process (GO:0031394),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
positive regulation of prostaglandin secretion (GO:0032308),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
membrane depolarization during AV node cell action potential (GO:0086045),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
membrane depolarization during SA node cell action potential (GO:0086046),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,SCN5A
positive regulation of T-helper 1 cell cytokine production (GO:2000556),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,IL1B
mitochondrial DNA repair (GO:0043504),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,LIG3
proline biosynthetic process (GO:0006561),05-Jan,0.059535202,0.333728565,0,0,20.32098765,57.32931659,ALDH18A1
"antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479)",3/73,0.059874002,0.333728565,0,0,3.500770599,9.856464766,PSMD14;PSME3;PSMD3
response to molecule of bacterial origin (GO:0002237),3/73,0.059874002,0.333728565,0,0,3.500770599,9.856464766,IL1B;CXCL2;S100A8
transcription-coupled nucleotide-excision repair (GO:0006283),3/73,0.059874002,0.333728565,0,0,3.500770599,9.856464766,COPS5;POLD2;LIG3
positive regulation of histone modification (GO:0031058),2/33,0.061118423,0.333728565,0,0,5.258597707,14.69747527,RUVBL2;IL1B
signal transduction by p53 class mediator (GO:0072331),2/33,0.061118423,0.333728565,0,0,5.258597707,14.69747527,MYBBP1A;RRP8
NIK/NF-kappaB signaling (GO:0038061),3/74,0.06186411,0.333728565,0,0,3.451288645,9.604298046,PSMD14;PSME3;PSMD3
inflammatory response (GO:0006954),6/230,0.063346528,0.333728565,0,0,2.198229292,6.06521177,IL1B;CXCL3;CXCL2;CD44;S100A8;CXCL5
mitochondrion organization (GO:0007005),5/175,0.063643812,0.333728565,0,0,2.410287965,6.639025337,CHCHD4;HAX1;TIMM23;PHB;HK2
fibroblast growth factor receptor signaling pathway (GO:0008543),3/75,0.063884761,0.333728565,0,0,3.403181189,9.361043455,FLRT2;GTF2F1;GTF2F2
regulation of transcription from RNA polymerase II promoter in response to hypoxia (GO:0061418),3/75,0.063884761,0.333728565,0,0,3.403181189,9.361043455,PSMD14;PSME3;PSMD3
cell-substrate junction assembly (GO:0007044),2/34,0.064430779,0.333728565,0,0,5.094008264,13.9686052,PEAK1;ACTN1
epithelial tube morphogenesis (GO:0060562),2/34,0.064430779,0.333728565,0,0,5.094008264,13.9686052,PAK1;MET
positive regulation of DNA binding (GO:0043388),2/34,0.064430779,0.333728565,0,0,5.094008264,13.9686052,PINX1;PLAUR
transcription by RNA polymerase I (GO:0006360),2/34,0.064430779,0.333728565,0,0,5.094008264,13.9686052,POLR1B;POLR1E
non-canonical Wnt signaling pathway (GO:0035567),4/124,0.065507988,0.333728565,0,0,2.727222222,7.433271031,PSMD14;PSME3;PSMD3;NFATC1
semaphorin-plexin signaling pathway (GO:0071526),2/35,0.067802145,0.333728565,0,0,4.939393939,13.29270652,FLNA;MET
cellular response to UV (GO:0034644),3/77,0.068016516,0.333728565,0,0,3.310866883,8.899625827,RUVBL2;TIMP1;NOC2L
positive regulation of type I interferon production (GO:0032481),3/77,0.068016516,0.333728565,0,0,3.310866883,8.899625827,DHX33;POLR3G;DDX41
negative regulation of apoptotic signaling pathway (GO:2001234),3/78,0.070127016,0.333728565,0,0,3.266556017,8.680700036,PSME3;PLAUR;NOC2L
antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590),3/78,0.070127016,0.333728565,0,0,3.266556017,8.680700036,PSMD14;PSME3;PSMD3
purine nucleobase biosynthetic process (GO:0009113),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,PRPS1
regulation of 3'-UTR-mediated mRNA stabilization (GO:1905868),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,METTL16
regulation of adiponectin secretion (GO:0070163),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,IL1B
astrocyte development (GO:0014002),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EIF2B5
negative regulation of glucocorticoid receptor signaling pathway (GO:2000323),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,PHB
negative regulation of lipoprotein lipase activity (GO:0051005),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,ANGPTL4
regulation of collagen fibril organization (GO:1904026),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,AEBP1
negative regulation of trophoblast cell migration (GO:1901164),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,TIMP1
regulation of immature T cell proliferation in thymus (GO:0033084),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,IL1B
negative regulation of vitamin metabolic process (GO:0046137),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,PRMT3
chromatin organization involved in negative regulation of transcription (GO:0097549),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,HMGA2
regulation of macromolecule biosynthetic process (GO:0010556),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,MTPN
contact inhibition (GO:0060242),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,PAK1
nuclear polyadenylation-dependent ncRNA catabolic process (GO:0071046),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EXOSC9
nuclear polyadenylation-dependent rRNA catabolic process (GO:0071035),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EXOSC9
nuclear polyadenylation-dependent tRNA catabolic process (GO:0071038),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EXOSC9
regulation of mRNA export from nucleus (GO:0010793),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,NSUN2
peptidyl-diphthamide biosynthetic process from peptidyl-histidine (GO:0017183),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,DPH5
peptidyl-diphthamide metabolic process (GO:0017182),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,DPH5
regulation of protein targeting (GO:1903533),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,HAX1
positive regulation of autophagy of mitochondrion in response to mitochondrial depolarization (GO:1904925),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,HK2
regulation of ribonucleoprotein complex localization (GO:2000197),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,NSUN2
positive regulation of cholesterol storage (GO:0010886),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EHD1
galactose catabolic process (GO:0019388),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,GALK1
glandular epithelial cell differentiation (GO:0002067),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,WDR77
regulation of ventricular cardiac muscle cell membrane depolarization (GO:0060373),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,SCN5A
positive regulation of fever generation (GO:0031622),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,IL1B
positive regulation of granulocyte differentiation (GO:0030854),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,HAX1
positive regulation of histone phosphorylation (GO:0033129),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,IL1B
histone-serine phosphorylation (GO:0035404),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,HMGA2
positive regulation of microglial cell migration (GO:1904141),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,CSF1
snoRNA localization (GO:0048254),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,ZNHIT6
L-ornithine transmembrane transport (GO:1903352),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,SLC25A15
snRNA modification (GO:0040031),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,METTL16
tRNA surveillance (GO:0106354),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,EXOSC9
N-terminal peptidyl-methionine acetylation (GO:0017196),06-Jan,0.071011718,0.333728565,0,0,16.25596708,42.99557596,NAA20
endoderm formation (GO:0001706),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,HMGA2;ITGA7
platelet aggregation (GO:0070527),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,ACTN1;FLNA
regulation of sodium ion transport (GO:0002028),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,RANGRF;SCN5A
intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,MYBBP1A;RRP8
positive regulation of myeloid leukocyte differentiation (GO:0002763),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,HAX1;CSF1
telomere maintenance via telomere lengthening (GO:0010833),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,PINX1;GAR1
positive regulation of substrate adhesion-dependent cell spreading (GO:1900026),2/36,0.071230603,0.333728565,0,0,4.793874575,12.66461479,FLNA;P4HB
regulation of apoptotic process (GO:0042981),14/742,0.071456589,0.333757237,0,0,1.5909699,4.198036847,ACTN1;SIGMAR1;NME2;PLAUR;HMGA2;WDR73;RRP1B;PHB;COPS5;HAX1;APEX1;FLNA;ANGPTL4;CD44
Golgi organization (GO:0007030),4/130,0.075081156,0.336036047,0,0,2.596560847,6.722978147,NSFL1C;PRMT5;SEC23IP;SURF4
extracellular matrix organization (GO:0030198),7/300,0.075577059,0.336036047,0,0,1.961967714,5.066982708,FLRT2;ADAM12;TNC;ITGA7;TIMP1;P4HB;CD44
antigen receptor-mediated signaling pathway (GO:0050851),5/185,0.076673296,0.336036047,0,0,2.275220828,5.843226196,EIF2B5;PAK1;PSMD14;PSME3;PSMD3
cellular response to hypoxia (GO:0071456),4/131,0.076741917,0.336036047,0,0,2.575984252,6.61334297,PSMD14;PSME3;PSMD3;P4HB
tRNA aminoacylation (GO:0043039),2/38,0.078251302,0.336036047,0,0,4.527089073,11.53425248,AIMP2;PPA1
MAPK cascade (GO:0000165),7/303,0.078720949,0.336036047,0,0,1.941783556,4.9357147,PAK1;PSMD14;PSME3;IL1B;PSMD3;MET;CAMKK2
RNA metabolic process (GO:0016070),4/133,0.08011852,0.336036047,0,0,2.535788114,6.400958693,PABPC4;WDR74;GTF2F1;GTF2F2
regulation of nitric-oxide synthase activity (GO:0050999),2/39,0.081839892,0.336036047,0,0,4.40451195,11.02445147,NUS1;IL1B
purine-containing compound metabolic process (GO:0072521),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PRPS1
pyrimidine-containing compound biosynthetic process (GO:0072528),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PRPS1
negative regulation of double-strand break repair via nonhomologous end joining (GO:2001033),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,HMGA2
astrocyte differentiation (GO:0048708),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,EIF2B5
regulation of atrial cardiac muscle cell membrane depolarization (GO:0060371),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,SCN5A
AV node cell action potential (GO:0086016),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,SCN5A
AV node cell to bundle of His cell communication (GO:0086067),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,SCN5A
regulation of calcidiol 1-monooxygenase activity (GO:0060558),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
negative regulation of membrane protein ectodomain proteolysis (GO:0051045),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,TIMP1
cardiolipin biosynthetic process (GO:0032049),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,TAMM41
regulation of glucocorticoid receptor signaling pathway (GO:2000322),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PHB
citrulline metabolic process (GO:0000052),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,ALDH18A1
regulation of metallopeptidase activity (GO:1905048),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,TIMP1
regulation of microglial cell migration (GO:1904139),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,CSF1
regulation of muscle organ development (GO:0048634),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,MTPN
DNA ligation (GO:0006266),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,LIG3
dolichyl diphosphate biosynthetic process (GO:0006489),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,NUS1
dolichyl diphosphate metabolic process (GO:0046465),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,NUS1
regulation of prostaglandin biosynthetic process (GO:0031392),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
endothelial cell morphogenesis (GO:0001886),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,MET
regulation of vascular associated smooth muscle cell differentiation (GO:1905063),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,NFATC1
positive regulation of gliogenesis (GO:0014015),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
hexose catabolic process (GO:0019320),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,GALK1
positive regulation of icosanoid secretion (GO:0032305),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
positive regulation of integrin-mediated signaling pathway (GO:2001046),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,FLNA
positive regulation of intracellular estrogen receptor signaling pathway (GO:0033148),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PAK1
hyaluronan biosynthetic process (GO:0030213),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
ribose phosphate biosynthetic process (GO:0046390),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PRPS1
ribosomal small subunit export from nucleus (GO:0000056),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,NOP9
RIG-I signaling pathway (GO:0039529),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PHB
positive regulation of microtubule nucleation (GO:0090063),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,PAK1
SA node cell action potential (GO:0086015),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,SCN5A
serine transport (GO:0032329),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,SFXN1
positive regulation of striated muscle contraction (GO:0045989),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,GSTO1
tRNA threonylcarbamoyladenosine metabolic process (GO:0070525),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,TPRKB
mitochondrial DNA metabolic process (GO:0032042),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,LIG3
positive regulation of unsaturated fatty acid biosynthetic process (GO:2001280),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,IL1B
xenobiotic catabolic process (GO:0042178),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,GSTO1
proline metabolic process (GO:0006560),07-Jan,0.082348755,0.336036047,0,0,13.54595336,33.82142723,ALDH18A1
anaphase-promoting complex-dependent catabolic process (GO:0031145),3/84,0.083394847,0.339392435,0,0,3.02366682,7.511298637,PSMD14;PSME3;PSMD3
negative regulation of Wnt signaling pathway (GO:0030178),5/191,0.085132161,0.345088886,0,0,2.201151752,5.422648258,PSMD14;RUVBL2;PSME3;PSMD3;NFATC1
regulation of microtubule polymerization (GO:0031113),2/40,0.085478267,0.345088886,0,0,4.288386255,10.54725652,PAK1;MET
ribosomal small subunit biogenesis (GO:0042274),2/40,0.085478267,0.345088886,0,0,4.288386255,10.54725652,RIOK1;NOL11
"Wnt signaling pathway, planar cell polarity pathway (GO:0060071)",3/85,0.085703893,0.345088886,0,0,2.986641028,7.337749992,PSMD14;PSME3;PSMD3
nucleobase-containing compound catabolic process (GO:0034655),2/41,0.089164689,0.348053588,0,0,4.178215724,10.09987626,PABPC4;NUDT5
regulation of response to DNA damage stimulus (GO:2001020),2/41,0.089164689,0.348053588,0,0,4.178215724,10.09987626,SMYD2;HMGA2
regulation of viral transcription (GO:0046782),2/41,0.089164689,0.348053588,0,0,4.178215724,10.09987626,GTF2F1;GTF2F2
hexose metabolic process (GO:0019318),2/41,0.089164689,0.348053588,0,0,4.178215724,10.09987626,ADPGK;GALK1
regulation of programmed cell death (GO:0043067),5/194,0.089538757,0.348053588,0,0,2.165880764,5.226451577,HAX1;ACTN1;APEX1;NME2;PHB
regulation of transcription from RNA polymerase II promoter in response to stress (GO:0043618),3/87,0.090402709,0.348053588,0,0,2.915234143,7.006710009,PSMD14;PSME3;PSMD3
regulation of establishment of planar polarity (GO:0090175),3/88,0.092791781,0.348053588,0,0,2.880790823,6.848784071,PSMD14;PSME3;PSMD3
mitochondrial gene expression (GO:0140053),2/42,0.092897458,0.348053588,0,0,4.073553719,9.679818658,MRPS18B;MRPS18A
negative regulation of B cell apoptotic process (GO:0002903),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,NOC2L
negative regulation of cAMP-dependent protein kinase activity (GO:2000480),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,PRKAR2A
atrial cardiac muscle cell to AV node cell signaling (GO:0086026),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,SCN5A
regulation of cardiac muscle cell action potential involved in regulation of contraction (GO:0098909),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,RANGRF
regulation of cytoplasmic translational elongation (GO:1900247),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,DPH5
regulation of establishment of protein localization to mitochondrion (GO:1903747),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,HAX1
negative regulation of vascular associated smooth muscle cell differentiation (GO:1905064),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,NFATC1
peptidyl-proline hydroxylation to 4-hydroxy-L-proline (GO:0018401),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,P4HB
regulation of pattern recognition receptor signaling pathway (GO:0062207),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,ZDHHC5
regulation of protein ADP-ribosylation (GO:0010835),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,PUM3
entry of bacterium into host cell (GO:0035635),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,MET
establishment of protein localization to chromatin (GO:0071169),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,RUVBL2
regulation of stem cell division (GO:2000035),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,SMYD5
regulation of striated muscle tissue development (GO:0016202),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,MTPN
positive regulation of endocytic recycling (GO:2001137),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,EHD1
positive regulation of glial cell migration (GO:1903977),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,CSF1
positive regulation of homotypic cell-cell adhesion (GO:0034112),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,PLAUR
positive regulation of intracellular steroid hormone receptor signaling pathway (GO:0033145),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,PAK1
rRNA base methylation (GO:0070475),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,METTL16
positive regulation of monocyte chemotactic protein-1 production (GO:0071639),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,IL1B
positive regulation of ryanodine-sensitive calcium-release channel activity (GO:0060316),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,GSTO1
U4 snRNA 3'-end processing (GO:0034475),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,EXOSC9
progesterone receptor signaling pathway (GO:0050847),08-Jan,0.093548,0.348053588,0,0,11.61022928,27.50789107,PHB
chromatin organization (GO:0006325),4/142,0.096201101,0.356053098,0,0,2.369323671,5.54733182,PAK1;RUVBL2;HMGA2;NUDT5
negative regulation of proteolysis (GO:0045861),2/43,0.096674905,0.356053098,0,0,3.973997178,9.284852665,DNAJC1;TIMP1
tRNA aminoacylation for protein translation (GO:0006418),2/43,0.096674905,0.356053098,0,0,3.973997178,9.284852665,AIMP2;PPA1
positive regulation of binding (GO:0051099),3/90,0.097647483,0.356053098,0,0,2.814279582,6.547115803,PLAUR;NMD3;MET
protein-DNA complex assembly (GO:0065004),4/143,0.098075439,0.356053098,0,0,2.352158273,5.461754574,PSMD14;PSME3;PSMD3;ORC2
branching morphogenesis of an epithelial tube (GO:0048754),2/44,0.100495395,0.356053098,0,0,3.879181425,8.912975497,PAK1;MET
homotypic cell-cell adhesion (GO:0034109),2/44,0.100495395,0.356053098,0,0,3.879181425,8.912975497,ACTN1;FLNA
intracellular protein transmembrane transport (GO:0065002),2/44,0.100495395,0.356053098,0,0,3.879181425,8.912975497,CHCHD4;TIMM23
mRNA catabolic process (GO:0006402),2/44,0.100495395,0.356053098,0,0,3.879181425,8.912975497,EXOSC9;METTL16
regulation of angiogenesis (GO:0045765),5/203,0.10345143,0.356053098,0,0,2.066480707,4.688127765,IL1B;ADAM12;HMGA2;ANGPTL4;HK2
protein deacetylation (GO:0006476),2/45,0.104357326,0.356053098,0,0,3.788775706,8.562384699,FLNA;PHB
purine nucleobase metabolic process (GO:0006144),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,PRPS1
alpha-amino acid biosynthetic process (GO:1901607),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,ALDH18A1
regulation of cell adhesion molecule production (GO:0060353),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,IL1B
negative regulation of lipase activity (GO:0060192),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,ANGPTL4
CD40 signaling pathway (GO:0023035),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,PHB
regulation of endothelial cell development (GO:1901550),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,IL1B
regulation of epidermis development (GO:0045682),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NME2
regulation of gap junction assembly (GO:1903596),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,IL1B
negative regulation of smooth muscle cell differentiation (GO:0051151),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NFATC1
regulation of glial cell proliferation (GO:0060251),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,IL1B
nuclear RNA surveillance (GO:0071027),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,EXOSC9
nucleoside diphosphate catabolic process (GO:0009134),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NUDT5
nucleoside diphosphate phosphorylation (GO:0006165),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NME2
nucleoside triphosphate biosynthetic process (GO:0009142),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NME2
nucleotide phosphorylation (GO:0046939),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NME2
regulation of mitotic centrosome separation (GO:0046602),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,NSFL1C
ornithine metabolic process (GO:0006591),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,ALDH18A1
phosphatidylglycerol biosynthetic process (GO:0006655),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,TAMM41
positive regulation of autophagy of mitochondrion (GO:1903599),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,CAMKK2
galactose metabolic process (GO:0006012),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,GALK1
positive regulation of ligase activity (GO:0051351),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,AIMP2
interleukin-23-mediated signaling pathway (GO:0038155),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,P4HB
positive regulation of NLRP3 inflammasome complex assembly (GO:1900227),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,DHX33
L-ascorbic acid metabolic process (GO:0019852),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,GSTO1
tetrahydrofolate interconversion (GO:0035999),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,MTHFD2
mesodermal cell differentiation (GO:0048333),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,HMGA2
mitochondrial tRNA modification (GO:0070900),09-Jan,0.104611121,0.356053098,0,0,10.15843621,22.93272475,PUS1
positive regulation of peptidyl-serine phosphorylation (GO:0033138),3/93,0.10511954,0.356983135,0,0,2.720055325,6.127351947,PAK1;HAX1;CD44
interleukin-12-mediated signaling pathway (GO:0035722),2/46,0.10825913,0.359404435,0,0,3.702479339,8.231454161,GSTO1;P4HB
positive regulation of nucleocytoplasmic transport (GO:0046824),2/46,0.10825913,0.359404435,0,0,3.702479339,8.231454161,IL1B;FLNA
positive regulation of response to stimulus (GO:0048584),2/46,0.10825913,0.359404435,0,0,3.702479339,8.231454161,HMGA1;HMGA2
regulation of G2/M transition of mitotic cell cycle (GO:0010389),4/149,0.109674351,0.359404435,0,0,2.254137931,4.982185264,PSMD14;PSME3;PSMD3;PINX1
regulation of cell cycle phase transition (GO:1901987),3/95,0.110222326,0.359404435,0,0,2.660653076,5.867420639,PSMD14;PSME3;PSMD3
response to cytokine (GO:0034097),4/150,0.111665047,0.359404435,0,0,2.238584475,4.907540263,HAX1;IL1B;TIMP1;PTPN12
regulation of DNA binding (GO:0051101),2/47,0.112199268,0.359404435,0,0,3.620018365,7.918713462,PLAUR;HMGA2
telomere organization (GO:0032200),2/47,0.112199268,0.359404435,0,0,3.620018365,7.918713462,APEX1;POLD2
regulation of actin filament-based movement (GO:1903115),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,SCN5A
negative regulation of hormone secretion (GO:0046888),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,IL1B
negative regulation of lymphocyte apoptotic process (GO:0070229),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,NOC2L
negative regulation of peptidyl-lysine acetylation (GO:2000757),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,NOC2L
regulation of endoplasmic reticulum unfolded protein response (GO:1900101),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,COPS5
regulation of granulocyte differentiation (GO:0030852),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,HAX1
negative regulation of telomerase activity (GO:0051974),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,PINX1
negative regulation of transcription by competitive promoter binding (GO:0010944),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,PHB
negative regulation of transmembrane transport (GO:0034763),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,IL1B
regulation of histone phosphorylation (GO:0033127),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,IL1B
chylomicron assembly (GO:0034378),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,P4HB
nuclear mRNA surveillance (GO:0071028),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,EXOSC9
regulation of macrophage migration (GO:1905521),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,CSF1
"nuclear-transcribed mRNA catabolic process, exonucleolytic, 3'-5' (GO:0034427)",10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,EXOSC9
cytoplasmic pattern recognition receptor signaling pathway in response to virus (GO:0039528),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,PHB
nucleoside metabolic process (GO:0009116),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,NME4
regulation of protein localization to centrosome (GO:1904779),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,NSFL1C
positive regulation by symbiont of entry into host (GO:0075294),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,P4HB
formation of translation preinitiation complex (GO:0001731),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,DHX29
fructose 6-phosphate metabolic process (GO:0006002),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,HK2
genetic imprinting (GO:0071514),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,PRMT7
rRNA pseudouridine synthesis (GO:0031118),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,GAR1
positive regulation of monocyte differentiation (GO:0045657),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,CSF1
positive regulation of myoblast fusion (GO:1901741),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,EHD1
telomere maintenance in response to DNA damage (GO:0043247),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,APEX1
positive regulation of rRNA processing (GO:2000234),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,RIOK1
urea cycle (GO:0000050),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,SLC25A15
positive regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030949),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,IL1B
positive regulation of viral entry into host cell (GO:0046598),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,P4HB
production of siRNA involved in RNA interference (GO:0030422),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,TSNAX
monocyte activation (GO:0042117),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,CSF1
protein deneddylation (GO:0000338),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,COPS5
protein insertion into ER membrane by stop-transfer membrane-anchor sequence (GO:0045050),10-Jan,0.115539766,0.359404435,0,0,9.029263832,19.48642012,EMC6
cellular response to interleukin-12 (GO:0071349),2/48,0.116176235,0.359909234,0,0,3.541142652,7.622830016,GSTO1;P4HB
nucleus organization (GO:0006997),2/48,0.116176235,0.359909234,0,0,3.541142652,7.622830016,REEP3;WDR73
regulation of peptidyl-serine phosphorylation (GO:0033135),3/98,0.118051238,0.362528133,0,0,2.576239354,5.504487116,PAK1;HAX1;CD44
positive regulation of defense response (GO:0031349),3/98,0.118051238,0.362528133,0,0,2.576239354,5.504487116,IL1B;POLR3G;S100A8
RNA splicing (GO:0008380),3/98,0.118051238,0.362528133,0,0,2.576239354,5.504487116,PRPF3;DDX23;SNRNP48
intracellular protein transport (GO:0006886),7/336,0.118212663,0.362528133,0,0,1.744052428,3.724022906,EHD1;ARF3;SEC23IP;SURF4;XPO5;RANGRF;TNPO3
phosphate-containing compound metabolic process (GO:0006796),5/212,0.11837004,0.362528133,0,0,1.975724132,4.216076028,PAK1;PPA1;NUDT5;NADK;HK2
regulation of interferon-beta production (GO:0032648),2/49,0.120188555,0.362528133,0,0,3.465623352,7.342593601,TRAF3;POLR3G
RNA catabolic process (GO:0006401),2/49,0.120188555,0.362528133,0,0,3.465623352,7.342593601,PABPC4;METTL16
cellular response to interleukin-1 (GO:0071347),4/155,0.1218566,0.362528133,0,0,2.163907285,4.554830817,PSMD14;PSME3;IL1B;PSMD3
positive regulation of NF-kappaB transcription factor activity (GO:0051092),4/155,0.1218566,0.362528133,0,0,2.163907285,4.554830817,MTPN;DHX33;IL1B;S100A8
transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169),8/404,0.12258891,0.362528133,0,0,1.657250471,3.478434024,NUS1;PAK1;FLRT2;CSF1;ARPC1B;GTF2F1;GTF2F2;MET
regulation of complement activation (GO:0030449),2/50,0.124234782,0.362528133,0,0,3.393250689,7.076902888,IL1B;PHB
positive regulation of cell morphogenesis involved in differentiation (GO:0010770),2/50,0.124234782,0.362528133,0,0,3.393250689,7.076902888,FLNA;P4HB
positive regulation of cell cycle process (GO:0090068),3/101,0.126080855,0.362528133,0,0,2.496993818,5.17085439,NSFL1C;CSPP1;IL1B
actin filament depolymerization (GO:0030042),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,MICAL2
actin filament network formation (GO:0051639),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,ACTN1
protein oxidation (GO:0018158),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,CHCHD4
rDNA heterochromatin assembly (GO:0000183),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,RRP8
calcineurin-NFAT signaling cascade (GO:0033173),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,NFATC1
regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway (GO:2001267),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PLAUR
negative regulation of platelet-derived growth factor receptor signaling pathway (GO:0010642),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PTPN12
regulation of endocytic recycling (GO:2001135),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,EHD1
regulation of gene expression by genetic imprinting (GO:0006349),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PRMT7
cellular response to UV-A (GO:0071492),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,TIMP1
regulation of lamellipodium morphogenesis (GO:2000392),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,CD44
regulation of monocyte chemotactic protein-1 production (GO:0071637),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,IL1B
peptidyl-lysine monomethylation (GO:0018026),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,SMYD2
peptidyl-proline hydroxylation (GO:0019511),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,P4HB
regulation of T cell mediated immunity (GO:0002709),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,IL1B
glutamine family amino acid biosynthetic process (GO:0009084),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,ALDH18A1
glutathione biosynthetic process (GO:0006750),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,CNDP2
hepatocyte growth factor receptor signaling pathway (GO:0048012),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PAK1
positive regulation of macrophage differentiation (GO:0045651),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,CSF1
positive regulation of posttranscriptional gene silencing (GO:0060148),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,XPO5
telomere maintenance via recombination (GO:0000722),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,TPRKB
tetrahydrofolate metabolic process (GO:0046653),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,MTHFD2
mitochondrial protein processing (GO:0034982),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PMPCA
urate metabolic process (GO:0046415),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PRPS1
V(D)J recombination (GO:0033151),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,LIG3
protein kinase C-activating G protein-coupled receptor signaling pathway (GO:0007205),11-Jan,0.126335562,0.362528133,0,0,8.125925926,16.81102708,PRKD3
regulation of cell growth (GO:0001558),5/217,0.127074613,0.363960874,0,0,1.928633457,3.978733904,MTPN;EXOSC9;PHB;DNPH1;S100A8
regulation of substrate adhesion-dependent cell spreading (GO:1900024),2/51,0.128313503,0.366817132,0,0,3.323832012,6.824753709,FLNA;P4HB
mitotic sister chromatid segregation (GO:0000070),3/102,0.128800238,0.36751647,0,0,2.47164592,5.065620058,EML4;PINX1;RRS1
cellular response to lipid (GO:0071396),5/219,0.130636907,0.369609082,0,0,1.910413327,3.888328249,IL1B;RUVBL2;CXCL3;CXCL2;CXCL5
cartilage development (GO:0051216),2/52,0.132423329,0.369609082,0,0,3.257190083,6.585228773,HMGA2;CD44
negative regulation of protein metabolic process (GO:0051248),2/52,0.132423329,0.369609082,0,0,3.257190083,6.585228773,FLNA;PHB
positive regulation of protein localization to cell periphery (GO:1904377),2/52,0.132423329,0.369609082,0,0,3.257190083,6.585228773,ZDHHC5;RANGRF
positive regulation of protein localization to plasma membrane (GO:1903078),2/52,0.132423329,0.369609082,0,0,3.257190083,6.585228773,ZDHHC5;RANGRF
"positive regulation of transcription, DNA-templated (GO:0045893)",19/1183,0.134624781,0.369609082,0,0,1.348789614,2.704678951,NME2;HMGA1;HMGA2;NFATC1;RRP1B;PHB;MED4;GTF2F1;CAMKK2;FOSL1;DNAJC2;COPS5;HAX1;DHX33;IL1B;APEX1;RUVBL2;MET;PELP1
cellular macromolecule catabolic process (GO:0044265),2/53,0.136562904,0.369609082,0,0,3.193161562,6.357488663,PABPC4;FBXO17
positive regulation of NIK/NF-kappaB signaling (GO:1901224),2/53,0.136562904,0.369609082,0,0,3.193161562,6.357488663,IL1B;PHB
positive regulation of gene expression (GO:0010628),9/482,0.13678422,0.369609082,0,0,1.561306284,3.105985647,MYBBP1A;CSF1;IL1B;POLR1B;HMGA2;POLR1E;FAM98B;PHB;FAM98A
actin crosslink formation (GO:0051764),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,FLNA
purine nucleotide biosynthetic process (GO:0006164),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,PRPS1
regulation of actin filament depolymerization (GO:0030834),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,MTPN
regulation of B cell apoptotic process (GO:0002902),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NOC2L
negative regulation of glucose transmembrane transport (GO:0010829),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,IL1B
negative regulation of histone acetylation (GO:0035067),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NOC2L
calcineurin-mediated signaling (GO:0097720),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NFATC1
negative regulation of release of sequestered calcium ion into cytosol (GO:0051280),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,GSTO1
negative regulation of ryanodine-sensitive calcium-release channel activity (GO:0060315),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,GSTO1
chromatin assembly or disassembly (GO:0006333),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NOC2L
nonribosomal peptide biosynthetic process (GO:0019184),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,CNDP2
regulation of myoblast fusion (GO:1901739),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,EHD1
peptidyl-methionine modification (GO:0018206),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NAA20
regulation of oxidative stress-induced cell death (GO:1903201),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,P4HB
early endosome to Golgi transport (GO:0034498),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,SURF4
regulation of RNA export from nucleus (GO:0046831),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,NSUN2
positive regulation of leukocyte proliferation (GO:0070665),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,CSF1
positive regulation of neuroinflammatory response (GO:0150078),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,IL1B
positive regulation of T-helper 1 type immune response (GO:0002827),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,IL1B
very-low-density lipoprotein particle assembly (GO:0034379),12-Jan,0.137000117,0.369609082,0,0,7.386831276,14.68334745,P4HB
regulation of JNK cascade (GO:0046328),3/105,0.137081629,0.369609082,0,0,2.39858433,4.766415683,COPS5;TRAF3;IL1B
nucleotide-excision repair (GO:0006289),3/105,0.137081629,0.369609082,0,0,2.39858433,4.766415683,COPS5;POLD2;LIG3
negative regulation of apoptotic process (GO:0043066),9/485,0.140432828,0.377437288,0,0,1.551224745,3.045094497,COPS5;HAX1;NME2;PLAUR;FLNA;HMGA2;WDR73;ANGPTL4;CD44
nuclear membrane reassembly (GO:0031468),2/54,0.140730899,0.377437288,0,0,3.131595677,6.140763904,NSFL1C;REEP3
regulation of proteasomal protein catabolic process (GO:0061136),2/54,0.140730899,0.377437288,0,0,3.131595677,6.140763904,PSMD14;PSME3
negative regulation of canonical Wnt signaling pathway (GO:0090090),4/165,0.143369211,0.378307706,0,0,2.028467909,3.939958299,PSMD14;RUVBL2;PSME3;PSMD3
negative regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043154),2/55,0.144926012,0.378307706,0,0,3.072353033,5.934347978,PLAUR;CD44
positive regulation of transcription by RNA polymerase II (GO:0045944),15/908,0.145229242,0.378307706,0,0,1.38361443,2.669603522,NME2;HMGA1;MICAL2;HMGA2;NFATC1;RRP1B;MED4;GTF2F1;FOSL1;COPS5;HAX1;APEX1;RUVBL2;MET;PELP1
pyrimidine deoxyribonucleotide catabolic process (GO:0009223),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,DCTPP1
negative regulation of cellular senescence (GO:2000773),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HMGA2
negative regulation of chromatin organization (GO:1905268),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HMGA1
negative regulation of chromatin silencing (GO:0031936),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HMGA1
negative regulation of DNA-dependent DNA replication (GO:2000104),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,LIG3
atrial cardiac muscle cell action potential (GO:0086014),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,SCN5A
negative regulation of gene silencing (GO:0060969),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HMGA1
negative regulation of hydrogen peroxide-induced cell death (GO:1903206),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,MET
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:1902166),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,CD44
regulation of homotypic cell-cell adhesion (GO:0034110),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,PLAUR
cytoplasmic sequestering of protein (GO:0051220),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,FLNA
entry into host (GO:0044409),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,MET
positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002824),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,IL1B
establishment of protein localization to chromosome (GO:0070199),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,RUVBL2
positive regulation of fatty acid biosynthetic process (GO:0045723),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,LPGAT1
Golgi ribbon formation (GO:0090161),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,PRMT5
response to interleukin-6 (GO:0070741),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,PHB
positive regulation of protein localization to cell surface (GO:2000010),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,RANGRF
positive regulation of ruffle assembly (GO:1900029),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,FAM98A
positive regulation of sodium ion transport (GO:0010765),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,SCN5A
transcription preinitiation complex assembly (GO:0070897),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,POLR1E
negative regulation by host of viral transcription (GO:0043922),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HMGA2
protein localization to mitochondrion (GO:0070585),13-Jan,0.147535021,0.378307706,0,0,6.770919067,12.95743809,HK2
autophagosome organization (GO:1905037),2/56,0.149146969,0.38179612,0,0,3.015304561,5.737591142,NSFL1C;EMC6
"DNA-templated transcription, initiation (GO:0006352)",4/168,0.15009805,0.383583906,0,0,1.991056911,3.775972792,POLR1B;POLR1E;GTF2F1;GTF2F2
regulation of mitotic nuclear division (GO:0007088),2/57,0.153392522,0.387327492,0,0,2.960330579,5.549894959,PRMT5;IL1B
dicarboxylic acid metabolic process (GO:0043648),2/57,0.153392522,0.387327492,0,0,2.960330579,5.549894959,MTHFD2;ALDH18A1
regulation of cell cycle (GO:0051726),6/296,0.154791417,0.387327492,0,0,1.692205158,3.157107844,GADD45GIP1;BOP1;MYBBP1A;HMGA2;WDR12;RRP8
autophagosome assembly (GO:0000045),2/58,0.157661451,0.387327492,0,0,2.907319953,5.370707433,NSFL1C;EMC6
positive regulation of mitochondrion organization (GO:0010822),2/58,0.157661451,0.387327492,0,0,2.907319953,5.370707433,PLAUR;CAMKK2
quinone biosynthetic process (GO:1901663),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,COQ5
"negative regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043518)",14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,CD44
antiviral innate immune response (GO:0140374),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,PHB
regulation of cAMP-dependent protein kinase activity (GO:2000479),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,PRKAR2A
cardiolipin metabolic process (GO:0032048),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,TAMM41
negative regulation of TORC1 signaling (GO:1904262),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,ITFG2
regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:1902165),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,CD44
regulation of IRE1-mediated unfolded protein response (GO:1903894),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,COPS5
regulation of lamellipodium organization (GO:1902743),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,CD44
nucleoside phosphate biosynthetic process (GO:1901293),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,NME2
ovarian follicle development (GO:0001541),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,EIF2B5
pancreas development (GO:0031016),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,MET
regulation of trophoblast cell migration (GO:1901163),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,TIMP1
positive regulation of granulocyte macrophage colony-stimulating factor production (GO:0032725),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,IL1B
heterochromatin organization (GO:0070828),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,HMGA2
response to UV-A (GO:0070141),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,TIMP1
positive regulation of macrophage chemotaxis (GO:0010759),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,CSF1
tRNA wobble base modification (GO:0002097),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,KTI12
tRNA wobble uridine modification (GO:0002098),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,KTI12
vascular endothelial growth factor signaling pathway (GO:0038084),14-Jan,0.157941843,0.387327492,0,0,6.249762583,11.53411432,NUS1
activation of protein kinase activity (GO:0032147),3/114,0.162946276,0.390460549,0,0,2.203095211,3.997152144,PAK1;PRKAR2A;PHB
histone modification (GO:0016570),3/114,0.162946276,0.390460549,0,0,2.203095211,3.997152144,PRMT7;RUVBL2;PHB
positive regulation of protein metabolic process (GO:0051247),3/115,0.165906423,0.390460549,0,0,2.183313574,3.921954656,MTPN;CSF1;IL1B
negative regulation of androgen receptor signaling pathway (GO:0060766),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,PHB
protein trimerization (GO:0070206),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,SIGMAR1
negative regulation of cellular component movement (GO:0051271),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,ACTN1
Arp2/3 complex-mediated actin nucleation (GO:0034314),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,ARPC1B
regulation of endothelial cell chemotaxis (GO:2001026),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,MET
cellular response to arsenic-containing substance (GO:0071243),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,GSTO1
regulation of establishment of protein localization (GO:0070201),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,GAPVD1
cellular response to estrogen stimulus (GO:0071391),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,PELP1
regulation of extracellular matrix organization (GO:1903053),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,AEBP1
negative regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045869),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,HMGA2
regulation of macrophage differentiation (GO:0045649),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,CSF1
nucleobase-containing small molecule catabolic process (GO:0034656),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,NUDT5
endoplasmic reticulum tubular network organization (GO:0071786),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,REEP3
positive regulation of acute inflammatory response (GO:0002675),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,IL1B
fibrinolysis (GO:0042730),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,PLAUR
positive regulation of endothelial cell chemotaxis (GO:2001028),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,MET
histone mRNA catabolic process (GO:0071044),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,ERI1
positive regulation of keratinocyte differentiation (GO:0045618),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,NME2
positive regulation of membrane protein ectodomain proteolysis (GO:0051044),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,IL1B
positive regulation of osteoclast differentiation (GO:0045672),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,CSF1
positive regulation of pattern recognition receptor signaling pathway (GO:0062208),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,ZDHHC5
positive regulation of protein export from nucleus (GO:0046827),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,IL1B
macrophage differentiation (GO:0030225),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,CSF1
positive regulation of telomerase RNA localization to Cajal body (GO:1904874),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,RUVBL2
"tRNA splicing, via endonucleolytic cleavage and ligation (GO:0006388)",15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,FAM98B
ubiquinone biosynthetic process (GO:0006744),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,COQ5
ubiquinone metabolic process (GO:0006743),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,COQ5
mitotic recombination (GO:0006312),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,TPRKB
modulation by host of viral genome replication (GO:0044827),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,PHB
protein homotrimerization (GO:0070207),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,SIGMAR1
myoblast fusion (GO:0007520),15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,ADAM12
"protein localization to chromosome, telomeric region (GO:0070198)",15-Jan,0.168222134,0.390460549,0,0,5.803057025,10.34377475,PINX1
positive regulation of protein phosphorylation (GO:0001934),7/371,0.169336627,0.392447327,0,0,1.573515093,2.794353011,PAK1;HAX1;CSF1;IL1B;PLAUR;CD44;CAMKK2
"regulation of DNA-templated transcription, initiation (GO:2000142)",2/61,0.170596668,0.394163991,0,0,2.759069898,4.879285924,FOSL1;MED4
pattern recognition receptor signaling pathway (GO:0002221),2/61,0.170596668,0.394163991,0,0,2.759069898,4.879285924,TRAF3;S100A8
regulation of mitotic cell cycle (GO:0007346),4/178,0.173361006,0.394494724,0,0,1.875670498,3.286885812,PRMT5;PSMD14;PSME3;PSMD3
regulation of translation (GO:0006417),4/178,0.173361006,0.394494724,0,0,1.875670498,3.286885812,MTPN;NOLC1;PUS7;PUM3
positive regulation of nucleic acid-templated transcription (GO:1903508),9/511,0.174081687,0.394494724,0,0,1.468898873,2.567973989,DNAJC2;IL1B;NME2;HMGA1;HMGA2;NFATC1;PHB;MED4;CAMKK2
membrane organization (GO:0061024),5/242,0.174660924,0.394494724,0,0,1.722984305,3.006450406,NSFL1C;REEP3;M6PR;GAPVD1;AGFG1
regulation of protein binding (GO:0043393),3/118,0.174880657,0.394494724,0,0,2.126032834,3.70706033,PRMT7;NMD3;GTF2F1
double-strand break repair via nonhomologous end joining (GO:0006303),2/62,0.174947401,0.394494724,0,0,2.712947658,4.729400044,PSMD14;LIG3
RNA processing (GO:0006396),4/179,0.175753399,0.394494724,0,0,1.864857143,3.242377525,PRPF3;PABPC4;DDX23;SNRNP48
negative regulation of histone modification (GO:0031057),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,NOC2L
basement membrane organization (GO:0071711),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,FLRT2
regulation of cholesterol storage (GO:0010885),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,EHD1
regulation of chromatin silencing (GO:0031935),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,HMGA1
regulation of defense response to virus (GO:0050688),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,TRAF3
regulation of ERBB signaling pathway (GO:1901184),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,PTPN12
regulation of granulocyte macrophage colony-stimulating factor production (GO:0032645),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,IL1B
negative regulation of telomere maintenance (GO:0032205),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,PINX1
nuclear transport (GO:0051169),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,HMGA1
nucleoside diphosphate metabolic process (GO:0009132),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,NME2
odontogenesis of dentin-containing tooth (GO:0042475),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,SCN5A
oligodendrocyte development (GO:0014003),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,EIF2B5
regulation of monocyte differentiation (GO:0045655),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,CSF1
DNA unwinding involved in DNA replication (GO:0006268),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,HMGA1
positive regulation by host of viral transcription (GO:0043923),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,RRP1B
regulation of rRNA processing (GO:2000232),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,RIOK1
histone H2A acetylation (GO:0043968),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,RUVBL2
"RNA splicing, via endonucleolytic cleavage and ligation (GO:0000394)",16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,FAM98B
mesenchyme development (GO:0060485),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,HMGA2
positive regulation of syncytium formation by plasma membrane fusion (GO:0060143),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,EHD1
N-terminal protein amino acid acetylation (GO:0006474),16-Jan,0.178377426,0.394494724,0,0,5.415912209,9.336239783,NAA20
actin cytoskeleton reorganization (GO:0031532),2/63,0.179315784,0.394494724,0,0,2.668337624,4.585823381,PAK1;FLNA
COPII vesicle coating (GO:0048208),2/63,0.179315784,0.394494724,0,0,2.668337624,4.585823381,SEC23IP;CNIH1
positive regulation of viral process (GO:0048524),2/63,0.179315784,0.394494724,0,0,2.668337624,4.585823381,GTF2F1;GTF2F2
vesicle coating (GO:0006901),2/63,0.179315784,0.394494724,0,0,2.668337624,4.585823381,SEC23IP;CNIH1
"vesicle targeting, rough ER to cis-Golgi (GO:0048207)",2/63,0.179315784,0.394494724,0,0,2.668337624,4.585823381,SEC23IP;CNIH1
negative regulation of cell population proliferation (GO:0008285),7/379,0.182216356,0.400295845,0,0,1.539040878,2.62031025,PAK1;IL1B;PINX1;SMYD2;HMGA1;UTP20;PHB
positive regulation of DNA-binding transcription factor activity (GO:0051091),5/246,0.182842861,0.40109171,0,0,1.694039827,2.878390802,MTPN;COPS5;DHX33;IL1B;S100A8
negative regulation of intrinsic apoptotic signaling pathway (GO:2001243),2/64,0.183700745,0.401692717,0,0,2.625166622,4.448206318,PLAUR;NOC2L
regulation of cell-matrix adhesion (GO:0001952),2/65,0.188101235,0.401692717,0,0,2.583366129,4.31622348,CSF1;PEAK1
activation of protein kinase A activity (GO:0034199),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,PRKAR2A
negative regulation of cell aging (GO:0090344),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,HMGA2
pulmonary valve morphogenesis (GO:0003184),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,NFATC1
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,GSTO1
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator (GO:1902254),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,CD44
regulation of establishment of endothelial barrier (GO:1903140),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,IL1B
DNA biosynthetic process (GO:0071897),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,POLD2
regulation of NLRP3 inflammasome complex assembly (GO:1900225),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,DHX33
dolichol-linked oligosaccharide biosynthetic process (GO:0006488),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,NUS1
epithelial cell morphogenesis (GO:0003382),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,MET
regulation of stem cell proliferation (GO:0072091),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,HMGA2
regulation of transferase activity (GO:0051338),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,PINX1
RNA interference (GO:0016246),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,TSNAX
positive regulation of muscle hypertrophy (GO:0014742),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,MTPN
stem cell development (GO:0048864),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,NOLC1
tail-anchored membrane protein insertion into ER membrane (GO:0071816),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,EMC6
membrane depolarization during cardiac muscle cell action potential (GO:0086012),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,SCN5A
positive regulation of stem cell proliferation (GO:2000648),17-Jan,0.188409232,0.401692717,0,0,5.077160494,8.474486158,HMGA2
cellular response to organic substance (GO:0071310),3/123,0.190128134,0.401933666,0,0,2.036929461,3.381419097,HAX1;IL1B;PTPN12
endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888),4/185,0.190339232,0.401933666,0,0,1.802486188,2.990229713,CNIH1;RANGRF;TEX261;CNIH4
positive regulation of macromolecule metabolic process (GO:0010604),7/384,0.19046991,0.401933666,0,0,1.518237473,2.517634066,MTPN;CSF1;IL1B;HMGA2;FAM98B;PHB;FAM98A
cellular component disassembly (GO:0022411),2/66,0.192516229,0.401933666,0,0,2.542871901,4.189571716,TIMP1;CD44
extracellular matrix disassembly (GO:0022617),2/66,0.192516229,0.401933666,0,0,2.542871901,4.189571716,TIMP1;CD44
platelet degranulation (GO:0002576),3/125,0.196320221,0.401933666,0,0,2.003333107,3.26144267,ACTN1;FLNA;TIMP1
regulation of epidermal growth factor receptor signaling pathway (GO:0042058),2/67,0.196944724,0.401933666,0,0,2.503623649,4.067968273,PLAUR;PTPN12
transcription elongation from RNA polymerase II promoter (GO:0006368),2/67,0.196944724,0.401933666,0,0,2.503623649,4.067968273,GTF2F1;GTF2F2
positive regulation of phosphorylation (GO:0042327),5/253,0.197492525,0.401933666,0,0,1.645633689,2.669307605,PAK1;IL1B;PLAUR;MET;CAMKK2
pulmonary valve development (GO:0003177),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,NFATC1
"alternative mRNA splicing, via spliceosome (GO:0000380)",18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,RBM17
negative regulation of lipid catabolic process (GO:0050995),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,IL1B
negative regulation of Rho protein signal transduction (GO:0035024),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,MET
negative regulation of signal transduction by p53 class mediator (GO:1901797),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,CD44
chromatin disassembly (GO:0031498),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,HMGA1
nucleosome disassembly (GO:0006337),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,HMGA1
nucleotide biosynthetic process (GO:0009165),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,PRPS1
DNA strand elongation (GO:0022616),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,POLD2
regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902175),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,P4HB
phosphatidylglycerol acyl-chain remodeling (GO:0036148),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,LPGAT1
phosphatidylinositol acyl-chain remodeling (GO:0036149),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,LPGAT1
positive chemotaxis (GO:0050918),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,MET
positive regulation of amyloid-beta formation (GO:1902004),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,GSAP
regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045091),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,HMGA2
positive regulation of cardiac muscle hypertrophy (GO:0010613),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,MTPN
regulation of telomerase RNA localization to Cajal body (GO:1904872),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,RUVBL2
regulation of telomere maintenance via telomere lengthening (GO:1904356),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,PINX1
regulation of ventricular cardiac muscle cell membrane repolarization (GO:0060307),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,SCN5A
glycoprotein catabolic process (GO:0006516),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,FBXO17
positive regulation of fatty acid metabolic process (GO:0045923),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,LPGAT1
hyaluronan catabolic process (GO:0030214),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,CD44
positive regulation of macrophage derived foam cell differentiation (GO:0010744),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,CSF1
RNA destabilization (GO:0050779),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,METTL16
rRNA catabolic process (GO:0016075),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,EXOSC9
positive regulation of nitric-oxide synthase activity (GO:0051000),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,NUS1
triglyceride biosynthetic process (GO:0019432),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,LPGAT1
ventricular cardiac muscle cell action potential (GO:0086005),18-Jan,0.198319049,0.401933666,0,0,4.778261922,7.73064574,SCN5A
cellular response to oxygen-containing compound (GO:1901701),6/323,0.203294765,0.409738624,0,0,1.545926888,2.462813514,IL1B;RUVBL2;CXCL3;CXCL2;CXCL5;CAMKK2
negative regulation of cellular catabolic process (GO:0031330),2/69,0.205838309,0.409738624,0,0,2.428641914,3.83886763,TIMP1;MET
positive regulation of protein polymerization (GO:0032273),2/69,0.205838309,0.409738624,0,0,2.428641914,3.83886763,PAK1;MET
carbohydrate derivative catabolic process (GO:1901136),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,FBXO17
cardiac muscle cell contraction (GO:0086003),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,SCN5A
negative regulation of nervous system development (GO:0051961),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,IL1B
cellular response to glucagon stimulus (GO:0071377),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,PRKAR2A
regulation of glucose transmembrane transport (GO:0010827),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,IL1B
neural crest cell differentiation (GO:0014033),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,NOLC1
nuclear membrane organization (GO:0071763),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,NSFL1C
cytoplasmic translational initiation (GO:0002183),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,DHX29
regulation of neuroinflammatory response (GO:0150077),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,IL1B
peptidyl-lysine dimethylation (GO:0018027),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,SMYD2
positive regulation of actin cytoskeleton reorganization (GO:2000251),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,HAX1
establishment of skin barrier (GO:0061436),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,MET
regulation of stem cell population maintenance (GO:2000036),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,HMGA2
folic acid metabolic process (GO:0046655),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,MTHFD2
regulation of water loss via skin (GO:0033561),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,MET
positive regulation of macrophage migration (GO:1905523),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,CSF1
maintenance of protein localization in organelle (GO:0072595),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,HK2
mesenchymal cell development (GO:0014031),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,NOLC1
protein import into mitochondrial matrix (GO:0030150),19-Jan,0.208108353,0.409738624,0,0,4.512574303,7.083371675,TIMM23
positive regulation of macromolecule biosynthetic process (GO:0010557),3/129,0.208848124,0.410662503,0,0,1.939340051,3.037293483,MTPN;IL1B;NMD3
cellular response to light stimulus (GO:0071482),2/70,0.210301503,0.41191959,0,0,2.392805056,3.730892862,RUVBL2;NOC2L
COPII-coated vesicle budding (GO:0090114),2/70,0.210301503,0.41191959,0,0,2.392805056,3.730892862,SEC23IP;CNIH1
snRNA transcription by RNA polymerase II (GO:0042795),2/70,0.210301503,0.41191959,0,0,2.392805056,3.730892862,GTF2F1;GTF2F2
regulation of primary metabolic process (GO:0080090),3/130,0.212007974,0.41220439,0,0,1.92397164,2.984332805,PSMD14;PSME3;PSMD3
positive regulation of canonical Wnt signaling pathway (GO:0090263),3/130,0.212007974,0.41220439,0,0,1.92397164,2.984332805,PSMD14;PSME3;PSMD3
cellular response to tumor necrosis factor (GO:0071356),4/194,0.212897968,0.41220439,0,0,1.716315789,2.655041416,PSMD14;TRAF3;PSME3;PSMD3
regulation of cellular macromolecule biosynthetic process (GO:2000112),8/468,0.214034966,0.41220439,0,0,1.421960206,2.192116438,PRMT5;MTPN;MYBBP1A;HMGA1;NOLC1;HMGA2;PHB;PUM3
regulation of endopeptidase activity (GO:0052548),2/71,0.214774402,0.41220439,0,0,2.358006947,3.627008697,PSME3;TIMP1
Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096),2/71,0.214774402,0.41220439,0,0,2.358006947,3.627008697,PAK1;ARPC1B
gland development (GO:0048732),2/71,0.214774402,0.41220439,0,0,2.358006947,3.627008697,MET;GFER
snRNA transcription (GO:0009301),2/71,0.214774402,0.41220439,0,0,2.358006947,3.627008697,GTF2F1;GTF2F2
protein targeting to lysosome (GO:0006622),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,M6PR
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,PHB
protein-DNA complex disassembly (GO:0032986),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,HMGA1
cardiac ventricle development (GO:0003231),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,SCN5A
cellular modified amino acid biosynthetic process (GO:0042398),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,CNDP2
regulation of granulocyte chemotaxis (GO:0071622),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,CSF1
negative regulation of telomere maintenance via telomerase (GO:0032211),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,PINX1
nucleobase-containing compound biosynthetic process (GO:0034654),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,POLD2
oligodendrocyte differentiation (GO:0048709),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,EIF2B5
regulation of nuclear division (GO:0051783),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,PRMT5
regulation of protein kinase A signaling (GO:0010738),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,PRKAR2A
folic acid-containing compound metabolic process (GO:0006760),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,MTHFD2
positive regulation of epidermal cell differentiation (GO:0045606),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,NME2
inositol phosphate-mediated signaling (GO:0048016),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,NFATC1
positive regulation of nitrogen compound metabolic process (GO:0051173),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,MTPN
lipopolysaccharide-mediated signaling pathway (GO:0031663),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,IL1B
mesoderm formation (GO:0001707),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,HMGA2
miRNA metabolic process (GO:0010586),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,XPO5
production of small RNA involved in gene silencing by RNA (GO:0070918),20-Jan,0.217778604,0.41220439,0,0,4.274853801,6.516058384,TSNAX
cell morphogenesis involved in differentiation (GO:0000904),2/72,0.219256108,0.413968622,0,0,2.32420307,3.527012533,PEAK1;ACTN1
Fc-gamma receptor signaling pathway (GO:0038094),2/72,0.219256108,0.413968622,0,0,2.32420307,3.527012533,PAK1;ARPC1B
defense response to virus (GO:0051607),3/133,0.221548832,0.417277906,0,0,1.87928503,2.832293501,NDUFAF4;FLNA;PHB
regulation of actin filament polymerization (GO:0030833),2/73,0.223745746,0.417277906,0,0,2.291351414,3.430714302,MTPN;HAX1
chromatin assembly (GO:0031497),2/73,0.223745746,0.417277906,0,0,2.291351414,3.430714302,HMGA2;NOC2L
positive regulation of JNK cascade (GO:0046330),2/73,0.223745746,0.417277906,0,0,2.291351414,3.430714302,TRAF3;IL1B
endomembrane system organization (GO:0010256),4/199,0.225741525,0.417277906,0,0,1.671880342,2.488367566,NSFL1C;SEC23IP;REEP3;SURF4
actin nucleation (GO:0045010),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,ARPC1B
negative regulation of cell communication (GO:0010648),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,IL1B
purinergic nucleotide receptor signaling pathway (GO:0035590),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,IL1B
regulation of anoikis (GO:2000209),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,MYBBP1A
regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,GSTO1
regulation of cell-substrate junction assembly (GO:0090109),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,PEAK1
cellular response to estradiol stimulus (GO:0071392),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,RUVBL2
chondroitin sulfate biosynthetic process (GO:0030206),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,CHPF
regulation of lipid catabolic process (GO:0050994),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,IL1B
regulation of lipoprotein lipase activity (GO:0051004),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,ANGPTL4
nuclear envelope organization (GO:0006998),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,REEP3
regulation of transcription by RNA polymerase III (GO:0006359),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,POLR3G
regulation of transposition (GO:0010528),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,SMYD5
response to glucagon (GO:0033762),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,PRKAR2A
positive regulation of lipid storage (GO:0010884),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,EHD1
positive regulation of T cell cytokine production (GO:0002726),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,IL1B
myotube differentiation (GO:0014902),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,ADAM12
protein localization to chromatin (GO:0071168),21-Jan,0.227331244,0.417277906,0,0,4.06090535,6.015610371,RUVBL2
protein-containing complex assembly (GO:0065003),5/267,0.227927459,0.417436207,0,0,1.556581175,2.301759954,SEC23IP;CNIH1;ZNHIT6;TSPAN4;MDN1
regulation of stress fiber assembly (GO:0051492),2/74,0.228242458,0.417436207,0,0,2.259412305,3.33793554,PAK1;MET
Fc receptor mediated stimulatory signaling pathway (GO:0002431),2/74,0.228242458,0.417436207,0,0,2.259412305,3.33793554,PAK1;ARPC1B
amino acid import (GO:0043090),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,SFXN1
negative regulation of lipid biosynthetic process (GO:0051055),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,PRMT3
negative regulation of protein dephosphorylation (GO:0035308),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,TIPRL
cellular response to nerve growth factor stimulus (GO:1990090),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,EHD1
neuronal action potential (GO:0019228),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,SCN5A
regulation of macrophage chemotaxis (GO:0010758),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,CSF1
osteoclast differentiation (GO:0030316),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,CSF1
positive regulation of amyloid precursor protein catabolic process (GO:1902993),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,GSAP
positive regulation of calcium ion transmembrane transporter activity (GO:1901021),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,GSTO1
female gonad development (GO:0008585),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,EIF2B5
glutamate metabolic process (GO:0006536),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,ALDH18A1
glutathione derivative biosynthetic process (GO:1901687),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,GSTO1
glutathione derivative metabolic process (GO:1901685),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,GSTO1
positive regulation of lipid catabolic process (GO:0050996),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,IL1B
positive regulation of peptidase activity (GO:0010952),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,PSME3
positive regulation of translational initiation (GO:0045948),22-Jan,0.236767697,0.423707342,0,0,3.867332941,5.571572977,EIF2B5
regulation of cell division (GO:0051302),2/76,0.237253782,0.423707342,0,0,2.198123744,3.162275552,SMYD5;CSPP1
establishment of protein localization to organelle (GO:0072594),2/76,0.237253782,0.423707342,0,0,2.198123744,3.162275552,HK2;TNPO3
regulation of RNA splicing (GO:0043484),2/76,0.237253782,0.423707342,0,0,2.198123744,3.162275552,RRP1B;METTL16
water-soluble vitamin metabolic process (GO:0006767),2/76,0.237253782,0.423707342,0,0,2.198123744,3.162275552,GSTO1;MTHFD2
positive regulation of response to external stimulus (GO:0032103),3/139,0.240875691,0.429670151,0,0,1.795826214,2.556312436,IL1B;POLR3G;S100A8
proteasomal protein catabolic process (GO:0010498),4/205,0.241407775,0.430113852,0,0,1.621475954,2.304551503,NSFL1C;PSMD14;PSME3;PSMD3
import into nucleus (GO:0051170),2/77,0.241766776,0.430216944,0,0,2.168705234,3.079088116,SMN1;TNPO3
acylglycerol biosynthetic process (GO:0046463),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,LPGAT1
negative regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001240),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,IL1B
negative regulation of G protein-coupled receptor signaling pathway (GO:0045744),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,MET
negative regulation of GTPase activity (GO:0034260),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,RRP1B
negative regulation of phosphoprotein phosphatase activity (GO:0032515),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,TIPRL
negative regulation of signal transduction in absence of ligand (GO:1901099),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,IL1B
"nucleotide-excision repair, DNA damage recognition (GO:0000715)",23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,COPS5
regulation of mononuclear cell migration (GO:0071675),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,CSF1
regulation of protein export from nucleus (GO:0046825),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,IL1B
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,GSTO1
regulation of supramolecular fiber organization (GO:1902903),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,AEBP1
glucose 6-phosphate metabolic process (GO:0051156),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,HK2
positive regulation of interleukin-17 production (GO:0032740),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,PHB
positive regulation of JUN kinase activity (GO:0043507),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,PAK1
positive regulation of transcription initiation from RNA polymerase II promoter (GO:0060261),23-Jan,0.246089372,0.430216944,0,0,3.691358025,5.175507315,MED4
negative regulation of protein serine/threonine kinase activity (GO:0071901),2/78,0.246283613,0.430216944,0,0,2.140060896,2.998806363,IL1B;PRKAR2A
recombinational repair (GO:0000725),2/79,0.250803529,0.434511812,0,0,2.112160567,2.92129844,PSMD14;LIG3
organelle organization (GO:0006996),7/420,0.253924408,0.434511812,0,0,1.383322606,1.896146111,NSFL1C;SEC23IP;HAX1;SURF4;MICAL2;WDR73;PHB
regulation of cardiac muscle hypertrophy (GO:0010611),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,MTPN
negative regulation of lipid metabolic process (GO:0045833),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
regulation of cell size (GO:0008361),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,MTPN
canonical glycolysis (GO:0061621),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,HK2
negative regulation of stress fiber assembly (GO:0051497),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,MET
negative regulation of synaptic transmission (GO:0050805),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
defense response to fungus (GO:0050832),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,S100A8
regulation of monooxygenase activity (GO:0032768),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
DNA packaging (GO:0006323),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,NOC2L
establishment of mitotic spindle orientation (GO:0000132),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,NSFL1C
regulation of ruffle assembly (GO:1900027),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,FAM98A
glucose catabolic process to pyruvate (GO:0061718),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,HK2
regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030947),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
positive regulation of p38MAPK cascade (GO:1900745),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
positive regulation of viral life cycle (GO:1903902),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,P4HB
protein kinase B signaling (GO:0043491),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,IL1B
ncRNA 3'-end processing (GO:0043628),24-Jan,0.255297657,0.434511812,0,0,3.530685275,4.820533337,ERI1
negative regulation of extrinsic apoptotic signaling pathway (GO:2001237),2/80,0.255325781,0.434511812,0,0,2.08497563,2.846439955,IL1B;PSME3
regulation of NIK/NF-kappaB signaling (GO:1901222),2/80,0.255325781,0.434511812,0,0,2.08497563,2.846439955,IL1B;PHB
regulation of organelle organization (GO:0033043),2/80,0.255325781,0.434511812,0,0,2.08497563,2.846439955,SURF4;S100A8
regulation of protein localization to plasma membrane (GO:1903076),2/80,0.255325781,0.434511812,0,0,2.08497563,2.846439955,ZDHHC5;RANGRF
negative regulation of cellular process (GO:0048523),9/566,0.255692797,0.434649122,0,0,1.320073341,1.80028773,SMYD5;ACTN1;IL1B;PINX1;ARHGDIG;SMYD2;HMGA1;UTP20;PHB
ephrin receptor signaling pathway (GO:0048013),2/82,0.264374404,0.441529134,0,0,2.032644628,2.70420802,PAK1;ARPC1B
protein quality control for misfolded or incompletely synthesized proteins (GO:0006515),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,CLPP
acylglycerol homeostasis (GO:0055090),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,ANGPTL4
negative regulation of cell junction assembly (GO:1901889),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,IL1B
regulation of cAMP-mediated signaling (GO:0043949),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,PRKAR2A
regulation of cardiac muscle cell action potential (GO:0098901),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,RANGRF
cardiac conduction system development (GO:0003161),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,SCN5A
regulation of cholesterol transport (GO:0032374),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,NUS1
negative regulation of signaling (GO:0023057),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,IL1B
phosphatidylglycerol metabolic process (GO:0046471),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,LPGAT1
regulation of ryanodine-sensitive calcium-release channel activity (GO:0060314),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,GSTO1
positive regulation of ERBB signaling pathway (GO:1901186),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,PLAUR
response to hexose (GO:0009746),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,EIF2B5
positive regulation of lipid metabolic process (GO:0045834),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,IL1B
positive regulation of release of cytochrome c from mitochondria (GO:0090200),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,PLAUR
positive regulation of vascular endothelial growth factor production (GO:0010575),25-Jan,0.264393928,0.441529134,0,0,3.38340192,4.50099079,IL1B
positive regulation of protein modification process (GO:0031401),4/214,0.265347463,0.442634559,0,0,1.551269841,2.058093171,PAK1;IL1B;PLAUR;CAMKK2
extracellular structure organization (GO:0043062),4/216,0.270728337,0.449199955,0,0,1.536477987,2.007622686,ADAM12;TNC;ITGA7;CD44
negative regulation of cell development (GO:0010721),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,IL1B
purine-containing compound biosynthetic process (GO:0072522),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,PRPS1
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902230),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,CD44
cellular response to drug (GO:0035690),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,IL1B
negative regulation of telomere maintenance via telomere lengthening (GO:1904357),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,PINX1
negative regulation of transposition (GO:0010529),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,SMYD5
endothelial cell development (GO:0001885),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,MET
glial cell development (GO:0021782),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,EIF2B5
hippo signaling (GO:0035329),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,MOB1A
positive regulation of interleukin-2 production (GO:0032743),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,IL1B
membrane depolarization during action potential (GO:0086010),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,SCN5A
TOR signaling (GO:0031929),26-Jan,0.273379541,0.449199955,0,0,3.247901235,4.212184244,TIPRL
external encapsulating structure organization (GO:0045229),4/217,0.27342606,0.449199955,0,0,1.529186228,1.982932548,ADAM12;TNC;ITGA7;CD44
"retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890)",2/85,0.277947247,0.456133969,0,0,1.95887683,2.507996904,ARF3;SURF4
negative regulation of catalytic activity (GO:0043086),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,TIMP1
negative regulation of cation channel activity (GO:2001258),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,GSTO1
negative regulation of insulin receptor signaling pathway (GO:0046627),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,IL1B
chondroitin sulfate proteoglycan biosynthetic process (GO:0050650),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,CHPF
peptidyl-lysine methylation (GO:0018022),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,SMYD2
regulation of vascular endothelial growth factor production (GO:0010574),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,IL1B
positive regulation of nitric oxide biosynthetic process (GO:0045429),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,IL1B
positive regulation of nuclear division (GO:0051785),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,IL1B
protein export from nucleus (GO:0006611),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,XPO5
negative regulation of actin filament bundle assembly (GO:0032232),27-Jan,0.282255836,0.457617623,0,0,3.122823678,3.950188955,MET
regulation of neuron death (GO:1901214),2/86,0.282468849,0.457617623,0,0,1.935458481,2.446781456,CSF1;SIGMAR1
positive regulation of endothelial cell migration (GO:0010595),2/86,0.282468849,0.457617623,0,0,1.935458481,2.446781456,NUS1;MET
actin filament organization (GO:0007015),3/152,0.283575738,0.458921078,0,0,1.638057312,2.064404377,TPM4;ACTN1;FLNA
positive regulation of Wnt signaling pathway (GO:0030177),3/153,0.286892594,0.460661775,0,0,1.627053942,2.031616626,PSMD14;PSME3;PSMD3
calcium ion transmembrane transport (GO:0070588),2/87,0.286988052,0.460661775,0,0,1.912591152,2.387515637,PMPCA;PHB
positive regulation of protein kinase activity (GO:0045860),3/154,0.290212572,0.460661775,0,0,1.616196312,1.999463722,PAK1;CSF1;HMGA2
negative regulation of calcium ion transmembrane transporter activity (GO:1901020),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,GSTO1
negative regulation of cellular response to insulin stimulus (GO:1900077),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,IL1B
receptor clustering (GO:0043113),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,FLNA
negative regulation of phosphatase activity (GO:0010923),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,TIPRL
cellular response to epidermal growth factor stimulus (GO:0071364),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,PTPN12
regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001239),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,IL1B
cellular response to interleukin-6 (GO:0071354),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,PHB
regulation of immunoglobulin production (GO:0002637),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,PHB
cristae formation (GO:0042407),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,DNAJC11
regulation of phosphatase activity (GO:0010921),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,TIPRL
regulation of plasma membrane bounded cell projection organization (GO:0120035),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,NCS1
histone mRNA metabolic process (GO:0008334),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,ERI1
internal peptidyl-lysine acetylation (GO:0018393),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,RUVBL2
positive regulation of nitric oxide metabolic process (GO:1904407),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,IL1B
L-amino acid transport (GO:0015807),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,SFXN1
positive regulation of protein import into nucleus (GO:0042307),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,FLNA
protein depolymerization (GO:0051261),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,MICAL2
protein localization to lysosome (GO:0061462),28-Jan,0.291024139,0.460661775,0,0,3.007011126,3.711701372,M6PR
negative regulation of binding (GO:0051100),2/88,0.291504245,0.460941087,0,0,1.890255622,2.33011945,HMGA2;GTF2F1
positive regulation of inflammatory response (GO:0050729),2/89,0.296016829,0.467415255,0,0,1.868433552,2.274516978,IL1B;S100A8
regulation of cell differentiation (GO:0045595),3/156,0.296860757,0.467415255,0,0,1.594906842,1.93700173,CSF1;SMYD5;NSUN2
regulation of actin polymerization or depolymerization (GO:0008064),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,HAX1
regulation of DNA biosynthetic process (GO:2000278),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,PINX1
regulation of double-strand break repair via nonhomologous end joining (GO:2001032),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,HMGA2
regulation of fatty acid biosynthetic process (GO:0042304),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,LPGAT1
negative regulation of transferase activity (GO:0051348),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,PINX1
regulation of response to biotic stimulus (GO:0002831),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,TRAF3
establishment of mitotic spindle localization (GO:0040001),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,NSFL1C
glial cell differentiation (GO:0010001),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,EIF2B5
glycolytic process (GO:0006096),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,HK2
positive regulation of leukocyte migration (GO:0002687),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,CSF1
mismatch repair (GO:0006298),29-Jan,0.299685757,0.467415255,0,0,2.899470899,3.49392283,POLD2
negative regulation of translation (GO:0017148),2/90,0.300525223,0.467415255,0,0,1.847107438,2.220636138,METTL16;PUS7
mitochondrial respiratory chain complex assembly (GO:0033108),2/90,0.300525223,0.467415255,0,0,1.847107438,2.220636138,CHCHD4;NDUFAF4
protein complex oligomerization (GO:0051259),2/90,0.300525223,0.467415255,0,0,1.847107438,2.220636138,EHD1;ZNHIT6
cellular response to growth factor stimulus (GO:0071363),3/158,0.303518051,0.470623496,0,0,1.574166778,1.876901391,EHD1;PTPN12;CD44
cellular response to starvation (GO:0009267),3/158,0.303518051,0.470623496,0,0,1.574166778,1.876901391,MYBBP1A;ITFG2;RRP8
organonitrogen compound biosynthetic process (GO:1901566),3/158,0.303518051,0.470623496,0,0,1.574166778,1.876901391,SLC25A15;PRKD3;GSTO1
toll-like receptor signaling pathway (GO:0002224),2/91,0.305028859,0.470735746,0,0,1.826260563,2.168408444,TRAF3;S100A8
positive regulation of supramolecular fiber organization (GO:1902905),2/91,0.305028859,0.470735746,0,0,1.826260563,2.168408444,PAK1;MET
protein autophosphorylation (GO:0046777),3/159,0.306849426,0.470735746,0,0,1.56399617,1.847702134,PAK1;PEAK1;CAMKK2
cardiac muscle cell action potential (GO:0086001),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,SCN5A
chondroitin sulfate metabolic process (GO:0030204),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,CHPF
peptidyl-lysine trimethylation (GO:0018023),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,SMYD5
establishment of spindle orientation (GO:0051294),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,NSFL1C
positive regulation of endopeptidase activity (GO:0010950),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,PSME3
heterotypic cell-cell adhesion (GO:0034113),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,ITGA7
ion homeostasis (GO:0050801),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,RANGRF
snRNA 3'-end processing (GO:0034472),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,EXOSC9
positive regulation of protein import (GO:1904591),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,FLNA
positive regulation of small GTPase mediated signal transduction (GO:0051057),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,LRRC59
TRIF-dependent toll-like receptor signaling pathway (GO:0035666),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,TRAF3
ncRNA catabolic process (GO:0034661),30-Jan,0.308241984,0.470735746,0,0,2.79934724,3.294468185,EXOSC9
regulation of peptidyl-tyrosine phosphorylation (GO:0050730),2/92,0.309527185,0.472223384,0,0,1.805876951,2.117768797,HAX1;CD44
positive regulation of protein kinase B signaling (GO:0051897),3/161,0.313516282,0.476926229,0,0,1.544041179,1.790939513,HAX1;PHB;MET
regulation of epithelial cell proliferation (GO:0050678),2/93,0.31401966,0.476926229,0,0,1.785941331,2.068655278,NME2;SCN5A
'de novo' posttranslational protein folding (GO:0051084),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,CHCHD4
protein palmitoylation (GO:0018345),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,ZDHHC5
negative regulation of DNA binding (GO:0043392),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,HMGA2
regulation of cellular component size (GO:0032535),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,MTPN
cardiac muscle cell action potential involved in contraction (GO:0086002),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,SCN5A
negative regulation of response to DNA damage stimulus (GO:2001021),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,CD44
regulation of macrophage derived foam cell differentiation (GO:0010743),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,CSF1
renal water homeostasis (GO:0003091),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,PRKAR2A
positive regulation of leukocyte cell-cell adhesion (GO:1903039),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,CD44
triglyceride homeostasis (GO:0070328),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,ANGPTL4
MyD88-independent toll-like receptor signaling pathway (GO:0002756),31-Jan,0.316694096,0.476926229,0,0,2.705898491,3.111293406,TRAF3
negative regulation of cellular protein metabolic process (GO:0032269),2/94,0.31850576,0.478231201,0,0,1.766439095,2.021008967,DNAJC1;PUS7
negative regulation of MAPK cascade (GO:0043409),2/94,0.31850576,0.478231201,0,0,1.766439095,2.021008967,IL1B;PHB
regulation of kinase activity (GO:0043549),2/94,0.31850576,0.478231201,0,0,1.766439095,2.021008967,MET;CAMKK2
mRNA metabolic process (GO:0016071),2/95,0.322984974,0.480912101,0,0,1.747356261,1.974773766,PRPF3;METTL16
activation of phospholipase C activity (GO:0007202),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PHB
negative regulation of DNA biosynthetic process (GO:2000279),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PINX1
aortic valve morphogenesis (GO:0003180),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,NFATC1
negative regulation of double-strand break repair (GO:2000780),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,HMGA2
negative regulation of intracellular steroid hormone receptor signaling pathway (GO:0033144),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PHB
regulation of cell morphogenesis (GO:0022604),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,CD44
regulation of intracellular estrogen receptor signaling pathway (GO:0033146),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PAK1
chondrocyte differentiation (GO:0002062),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,HMGA2
DNA damage checkpoint signaling (GO:0000077),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,TIPRL
ERBB2 signaling pathway (GO:0038128),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PTPN12
gene silencing by miRNA (GO:0035195),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,XPO5
membrane depolarization (GO:0051899),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,SCN5A
mitochondrial membrane organization (GO:0007006),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,DNAJC11
protein K63-linked deubiquitination (GO:0070536),1/32,0.325043356,0.480912101,0,0,2.618478694,2.942637718,PSMD14
regulation of MAPK cascade (GO:0043408),3/166,0.330195133,0.488058629,0,0,1.496296108,1.658003052,PAK1;DHX33;IL1B
double-strand break repair via homologous recombination (GO:0000724),2/97,0.331920759,0.488354975,0,0,1.710395824,1.886325456,PSMD14;LIG3
glycosaminoglycan biosynthetic process (GO:0006024),2/97,0.331920759,0.488354975,0,0,1.710395824,1.886325456,CHPF;IL1B
apoptotic mitochondrial changes (GO:0008637),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,HK2
regulation of interleukin-17 production (GO:0032660),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,PHB
regulation of protein localization to cell surface (GO:2000008),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,RANGRF
exonucleolytic catabolism of deadenylated mRNA (GO:0043928),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,EXOSC9
RNA stabilization (GO:0043489),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,NSUN2
positive regulation of organelle organization (GO:0010638),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,SURF4
mitotic G2 DNA damage checkpoint signaling (GO:0007095),1/33,0.33329101,0.488354975,0,0,2.536522634,2.786977016,HMGA2
protein polyubiquitination (GO:0000209),5/314,0.337654559,0.494092778,0,0,1.316637554,1.429515422,PSMD14;TRAF3;PSME3;PSMD3;FBXO17
response to UV (GO:0009411),2/99,0.340823185,0.494092778,0,0,1.67495953,1.802912125,RUVBL2;NOC2L
positive regulation of stress-activated MAPK cascade (GO:0032874),2/99,0.340823185,0.494092778,0,0,1.67495953,1.802912125,TRAF3;IL1B
regulation of amyloid-beta formation (GO:1902003),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,GSAP
cardiac muscle contraction (GO:0060048),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,SCN5A
cellular response to vascular endothelial growth factor stimulus (GO:0035924),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,NUS1
regulation of keratinocyte differentiation (GO:0045616),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,NME2
positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,PLAUR
histone lysine methylation (GO:0034968),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,SMYD2
positive regulation of pri-miRNA transcription by RNA polymerase II (GO:1902895),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,FOSL1
positive regulation of release of sequestered calcium ion into cytosol (GO:0051281),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,GSTO1
tRNA methylation (GO:0030488),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,NSUN2
protein localization to chromosome (GO:0034502),1/34,0.34143829,0.494092778,0,0,2.459533608,2.642986087,PINX1
negative regulation of neurogenesis (GO:0050768),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,IL1B
negative regulation of Ras protein signal transduction (GO:0046580),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,MET
cellular response to hydrogen peroxide (GO:0070301),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,SIGMAR1
cellular response to virus (GO:0098586),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,RRP1B
regulation of JUN kinase activity (GO:0043506),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,PAK1
"nuclear-transcribed mRNA catabolic process, exonucleolytic (GO:0000291)",1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,EXOSC9
oxoacid metabolic process (GO:0043436),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,PPA1
peptidyl-tyrosine dephosphorylation (GO:0035335),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,PTPN12
regulation of protein polymerization (GO:0032271),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,HAX1
regulation of TORC1 signaling (GO:1903432),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,ITFG2
response to estrogen (GO:0043627),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,PELP1
positive regulation of immunoglobulin production (GO:0002639),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,PHB
positive regulation of lipid biosynthetic process (GO:0046889),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,LPGAT1
protein localization to cilium (GO:0061512),1/35,0.349486411,0.498897866,0,0,2.387073348,2.509507771,EHD1
positive regulation of protein localization to membrane (GO:1905477),2/101,0.349688623,0.498897866,0,0,1.640955005,1.724171394,ZDHHC5;RANGRF
regulation of protein catabolic process (GO:0042176),2/102,0.35410639,0.501005284,0,0,1.62446281,1.686448859,FLNA;PHB
intrinsic apoptotic signaling pathway (GO:0097193),2/102,0.35410639,0.501005284,0,0,1.62446281,1.686448859,MYBBP1A;RRP8
proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161),5/321,0.354534449,0.501005284,0,0,1.287008103,1.334562745,NSFL1C;PSMD14;PSME3;PSMD3;FBXO17
negative regulation of cellular protein localization (GO:1903828),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,NSFL1C
aortic valve development (GO:0003176),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,NFATC1
regulation of androgen receptor signaling pathway (GO:0060765),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,PHB
regulation of cardiac muscle contraction (GO:0055117),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,SCN5A
regulation of cell cycle G1/S phase transition (GO:1902806),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,PSME3
regulation of mRNA processing (GO:0050684),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,METTL16
regulation of osteoclast differentiation (GO:0045670),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,CSF1
regulation of protein import into nucleus (GO:0042306),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,FLNA
positive regulation of cytokine-mediated signaling pathway (GO:0001961),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,CSF1
positive regulation of innate immune response (GO:0045089),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,POLR3G
positive regulation of interferon-beta production (GO:0032728),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,POLR3G
positive regulation of mitotic nuclear division (GO:0045840),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,IL1B
membrane assembly (GO:0071709),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,NSFL1C
membrane fusion (GO:0061025),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,NSFL1C
positive regulation of T cell mediated immunity (GO:0002711),1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,IL1B
"Wnt signaling pathway, calcium modulating pathway (GO:0007223)",1/36,0.357436576,0.501005284,0,0,2.318753674,2.385527617,NFATC1
regulation of actin cytoskeleton reorganization (GO:2000249),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,HAX1
"nucleotide-excision repair, DNA incision, 5'-to lesion (GO:0006296)",1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,POLD2
regulation of p38MAPK cascade (GO:1900744),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,IL1B
phospholipid biosynthetic process (GO:0008654),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,NUS1
positive regulation of cytokinesis (GO:0032467),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,CSPP1
regulation of transport (GO:0051049),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,GAPVD1
glutamine family amino acid metabolic process (GO:0009064),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,ALDH18A1
lysosome localization (GO:0032418),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,FAM98A
protein insertion into ER membrane (GO:0045048),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,EMC6
ncRNA metabolic process (GO:0034660),1/37,0.365289972,0.507328617,0,0,2.254229538,2.270152955,XPO5
positive regulation of signal transduction (GO:0009967),4/252,0.36961672,0.510168036,0,0,1.311021505,1.304844894,IL1B;ZDHHC5;FLNA;PHB
cellular protein modification process (GO:0006464),14/1025,0.370868254,0.510168036,0,0,1.128585559,1.119453484,NUS1;CSF1;PSMD14;FBXO17;TNC;PTPN12;CAMKK2;PAK1;COPS5;PEAK1;PSME3;PSMD3;TIMP1;P4HB
regulation of cell cycle process (GO:0010564),2/106,0.371668304,0.510168036,0,0,1.561665607,1.545663967,PRMT5;HMGA2
chromosome organization (GO:0051276),2/106,0.371668304,0.510168036,0,0,1.561665607,1.545663967,COPS5;HMGA2
RNA export from nucleus (GO:0006405),2/106,0.371668304,0.510168036,0,0,1.561665607,1.545663967,XPO5;AGFG1
positive regulation of protein serine/threonine kinase activity (GO:0071902),2/106,0.371668304,0.510168036,0,0,1.561665607,1.545663967,IL1B;HMGA2
neutrophil degranulation (GO:0043312),7/481,0.372111436,0.510168036,0,0,1.201499048,1.187756193,PSMD14;PSMD3;SURF4;NME2;PLAUR;CD44;S100A8
regulation of canonical Wnt signaling pathway (GO:0060828),4/253,0.372381766,0.510168036,0,0,1.305689424,1.289806623,PSMD14;PSME3;RUVBL2;PSMD3
actin-myosin filament sliding (GO:0033275),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,TPM4
negative regulation of TOR signaling (GO:0032007),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,ITFG2
connective tissue development (GO:0061448),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,CD44
regulation of phosphoprotein phosphatase activity (GO:0043666),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,TIPRL
response to estradiol (GO:0032355),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,RUVBL2
positive regulation of potassium ion transport (GO:0043268),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,FLNA
positive regulation of production of molecular mediator of immune response (GO:0002702),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,PHB
mRNA destabilization (GO:0061157),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,METTL16
muscle filament sliding (GO:0030049),1/38,0.373047773,0.510168036,0,0,2.193193193,2.162595493,TPM4
cellular protein localization (GO:0034613),5/329,0.373870347,0.510692195,0,0,1.25471357,1.234445188,EHD1;ARF3;SEC23IP;USP4;FLNA
cellular response to cytokine stimulus (GO:0071345),7/482,0.374103901,0.510692195,0,0,1.198907395,1.17879178,HAX1;CSF1;IL1B;TIMP1;PHB;PTPN12;CXCL2
regulated exocytosis (GO:0045055),3/180,0.376756273,0.512339988,0,0,1.376960405,1.344129251,ACTN1;FLNA;TIMP1
positive regulation of cellular biosynthetic process (GO:0031328),3/180,0.376756273,0.512339988,0,0,1.376960405,1.344129251,LPGAT1;IL1B;NMD3
neutrophil activation involved in immune response (GO:0002283),7/485,0.38008478,0.512339988,0,0,1.1911975,1.152317941,PSMD14;PSMD3;SURF4;NME2;PLAUR;CD44;S100A8
DNA replication (GO:0006260),2/108,0.380378437,0.512339988,0,0,1.532044285,1.480856596,ORC2;POLD2
negative regulation of protein secretion (GO:0050709),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,IL1B
regulation of heart rate by cardiac conduction (GO:0086091),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,SCN5A
regulation of ion transmembrane transporter activity (GO:0032412),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,RANGRF
"nucleotide-excision repair, DNA incision (GO:0033683)",1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,POLD2
odontogenesis (GO:0042476),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,SCN5A
DNA integrity checkpoint signaling (GO:0031570),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,TIPRL
regulation of protein targeting to mitochondrion (GO:1903214),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,HAX1
regulation of viral entry into host cell (GO:0046596),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,P4HB
response to peptide (GO:1901652),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,EIF2B5
positive regulation of intracellular transport (GO:0032388),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,EHD1
membrane protein proteolysis (GO:0033619),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,CLPP
protein acylation (GO:0043543),1/39,0.380711137,0.512339988,0,0,2.135369287,2.062156788,ZDHHC5
neutrophil mediated immunity (GO:0002446),7/488,0.386069778,0.517580191,0,0,1.183583779,1.126460655,PSMD14;PSMD3;SURF4;NME2;PLAUR;CD44;S100A8
negative regulation of blood coagulation (GO:0030195),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,PLAUR
negative regulation of ERBB signaling pathway (GO:1901185),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,PTPN12
carboxylic acid metabolic process (GO:0019752),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,GSTO1
nucleocytoplasmic transport (GO:0006913),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,SMN1
regulation of nitric oxide biosynthetic process (GO:0045428),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,IL1B
positive regulation of cation channel activity (GO:2001259),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,GSTO1
regulation of sodium ion transmembrane transporter activity (GO:2000649),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,RANGRF
positive regulation of intrinsic apoptotic signaling pathway (GO:2001244),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,S100A8
stem cell differentiation (GO:0048863),1/40,0.388281209,0.517580191,0,0,2.08051071,1.96821605,HMGA2
positive regulation of cytokine production (GO:0001819),5/335,0.388375785,0.517580191,0,0,1.231520223,1.164749525,DHX33;IL1B;POLR3G;PHB;DDX41
regulation of protein kinase activity (GO:0045859),2/110,0.389037548,0.517580191,0,0,1.503520049,1.419442329,CSF1;CAMKK2
response to endoplasmic reticulum stress (GO:0034976),2/110,0.389037548,0.517580191,0,0,1.503520049,1.419442329,EIF2B5;P4HB
cellular component assembly (GO:0022607),4/261,0.394461376,0.523312148,0,0,1.264526589,1.176305688,TSPAN4;FLNA;NOC2L;MDN1
regulation of cell development (GO:0060284),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,IL1B
carbohydrate catabolic process (GO:0016052),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,HK2
regulation of protein dephosphorylation (GO:0035304),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,TIPRL
regulation of release of cytochrome c from mitochondria (GO:0090199),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,PLAUR
positive regulation of cation transmembrane transport (GO:1904064),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,FLNA
heart contraction (GO:0060047),1/41,0.395759121,0.523312148,0,0,2.028395062,1.880219856,SCN5A
protein-containing complex subunit organization (GO:0043933),2/112,0.397642991,0.52443272,0,0,1.476033058,1.361198694,TSPAN4;MDN1
regulation of cytoskeleton organization (GO:0051493),2/112,0.397642991,0.52443272,0,0,1.476033058,1.361198694,PAK1;S100A8
phosphatidylinositol metabolic process (GO:0046488),2/112,0.397642991,0.52443272,0,0,1.476033058,1.361198694,ARF3;LPGAT1
regulation of mitotic cell cycle phase transition (GO:1901990),3/188,0.403093123,0.529390667,0,0,1.316877874,1.196498996,PSMD14;PSME3;PSMD3
nucleic acid-templated transcription (GO:0097659),1/42,0.403145989,0.529390667,0,0,1.97882164,1.797673434,PWP1
regulation of nervous system development (GO:0051960),1/42,0.403145989,0.529390667,0,0,1.97882164,1.797673434,IL1B
positive regulation of epithelial to mesenchymal transition (GO:0010718),1/42,0.403145989,0.529390667,0,0,1.97882164,1.797673434,IL1B
translesion synthesis (GO:0019985),1/42,0.403145989,0.529390667,0,0,1.97882164,1.797673434,POLD2
response to lipid (GO:0033993),2/114,0.406192275,0.532469667,0,0,1.449527745,1.30592107,IL1B;S100A8
positive regulation of kinase activity (GO:0033674),2/114,0.406192275,0.532469667,0,0,1.449527745,1.30592107,CSF1;MET
regulation of protein phosphorylation (GO:0001932),4/266,0.408205113,0.533895196,0,0,1.240076336,1.11109042,PAK1;IL1B;PLAUR;CAMKK2
cellular glucose homeostasis (GO:0001678),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,HK2
development of primary male sexual characteristics (GO:0046546),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,MEA1
DNA synthesis involved in DNA repair (GO:0000731),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,POLD2
glutathione metabolic process (GO:0006749),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,CNDP2
heart looping (GO:0001947),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,MICAL2
positive regulation of phospholipase C activity (GO:0010863),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,PHB
male gonad development (GO:0008584),1/43,0.410442918,0.533895196,0,0,1.931608858,1.720133258,MEA1
cellular amide metabolic process (GO:0043603),2/115,0.410445121,0.533895196,0,0,1.436626929,1.279335024,MTHFD2;AEBP1
cation transmembrane transport (GO:0098655),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,SFXN1
positive regulation of biosynthetic process (GO:0009891),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,MTPN
positive regulation of cell division (GO:0051781),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,CSPP1
positive regulation of cell-matrix adhesion (GO:0001954),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,CSF1
positive regulation of mRNA catabolic process (GO:0061014),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,METTL16
intracellular steroid hormone receptor signaling pathway (GO:0030518),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,PHB
positive regulation of potassium ion transmembrane transport (GO:1901381),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,FLNA
positive regulation of stress fiber assembly (GO:0051496),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,PAK1
mitotic spindle assembly (GO:0090307),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,FLNA
protein K63-linked ubiquitination (GO:0070534),1/44,0.417650998,0.538652689,0,0,1.886592018,1.647200713,TRAF3
action potential (GO:0001508),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,SCN5A
amino acid transmembrane transport (GO:0003333),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,SFXN1
regulation of insulin receptor signaling pathway (GO:0046626),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,IL1B
neural crest cell development (GO:0014032),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,NOLC1
regulation of pri-miRNA transcription by RNA polymerase II (GO:1902893),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,FOSL1
positive regulation of chemotaxis (GO:0050921),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,MET
positive regulation of response to biotic stimulus (GO:0002833),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,POLR3G
mitotic G2/M transition checkpoint (GO:0044818),1/45,0.424771307,0.544137421,0,0,1.843621399,1.578516675,HMGA2
alpha-amino acid metabolic process (GO:1901605),1/46,0.431804908,0.55128667,0,0,1.802560585,1.51375684,ALDH18A1
regulation of telomerase activity (GO:0051972),1/46,0.431804908,0.55128667,0,0,1.802560585,1.51375684,PINX1
positive regulation of smooth muscle cell proliferation (GO:0048661),1/46,0.431804908,0.55128667,0,0,1.802560585,1.51375684,PHB
postreplication repair (GO:0006301),1/46,0.431804908,0.55128667,0,0,1.802560585,1.51375684,POLD2
protein homooligomerization (GO:0051260),2/121,0.435640045,0.55571562,0,0,1.363775262,1.133214001,EHD1;SIGMAR1
determination of heart left/right asymmetry (GO:0061371),1/47,0.438752855,0.557811419,0,0,1.763285024,1.4526277,MICAL2
embryonic heart tube morphogenesis (GO:0003143),1/47,0.438752855,0.557811419,0,0,1.763285024,1.4526277,MICAL2
epithelial to mesenchymal transition (GO:0001837),1/47,0.438752855,0.557811419,0,0,1.763285024,1.4526277,HMGA2
histone deacetylation (GO:0016575),1/47,0.438752855,0.557811419,0,0,1.763285024,1.4526277,PHB
positive regulation of epithelial cell proliferation (GO:0050679),2/123,0.443909717,0.56276653,0,0,1.34109692,1.089150508,NME2;SCN5A
negative regulation of MAP kinase activity (GO:0043407),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,IL1B
regulation of interleukin-2 production (GO:0032663),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,IL1B
regulation of mitochondrion organization (GO:0010821),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,HAX1
positive regulation of blood vessel endothelial cell migration (GO:0043536),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,NUS1
histone H4 acetylation (GO:0043967),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,RUVBL2
substrate adhesion-dependent cell spreading (GO:0034446),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,PEAK1
myelination (GO:0042552),1/48,0.445616185,0.56276653,0,0,1.725680764,1.394863048,EIF2B5
defense response to symbiont (GO:0140546),2/124,0.448019418,0.565283273,0,0,1.33003658,1.067911247,NDUFAF4;FLNA
generation of neurons (GO:0048699),3/202,0.448353795,0.565283273,0,0,1.223357451,0.981343872,MTPN;IL1B;MET
regulation of protein secretion (GO:0050708),2/125,0.452112086,0.567082588,0,0,1.319156084,1.047179278,DNAJC1;IL1B
cellular defense response (GO:0006968),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,FOSL1
cellular response to mechanical stimulus (GO:0071260),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,IL1B
regulation of smooth muscle cell proliferation (GO:0048660),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,PHB
regulation of stress-activated MAPK cascade (GO:0032872),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,COPS5
response to glucose (GO:0009749),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,EIF2B5
inner mitochondrial membrane organization (GO:0007007),1/49,0.452395925,0.567082588,0,0,1.689643347,1.34022095,DNAJC11
actin polymerization or depolymerization (GO:0008154),1/50,0.459093089,0.57358297,0,0,1.655076846,1.288481101,MICAL2
negative regulation of ERK1 and ERK2 cascade (GO:0070373),1/50,0.459093089,0.57358297,0,0,1.655076846,1.288481101,PHB
regulation of cellular component movement (GO:0051270),1/50,0.459093089,0.57358297,0,0,1.655076846,1.288481101,ACTN1
positive regulation of ion transport (GO:0043270),1/50,0.459093089,0.57358297,0,0,1.655076846,1.288481101,SCN5A
regulation of protein kinase B signaling (GO:0051896),3/207,0.464192547,0.57709859,0,0,1.193068099,0.91562708,HAX1;PHB;MET
proteolysis (GO:0006508),4/287,0.465098644,0.57709859,0,0,1.146819788,0.87789715,CLPP;LAP3;AEBP1;CNDP2
regulation of axonogenesis (GO:0050770),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,PAK1
DNA duplex unwinding (GO:0032508),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,HMGA1
regulation of protein modification process (GO:0031399),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,PUM3
positive regulation of actin filament bundle assembly (GO:0032233),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,PAK1
gonad development (GO:0008406),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,MEA1
mesenchymal cell differentiation (GO:0048762),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,HMGA2
mitotic nuclear membrane organization (GO:0101024),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,REEP3
mitotic nuclear membrane reassembly (GO:0007084),1/51,0.465708678,0.57709859,0,0,1.621893004,1.239442516,REEP3
negative regulation of cellular biosynthetic process (GO:0031327),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,PRMT3
amide biosynthetic process (GO:0043604),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,SLC25A15
endocytic recycling (GO:0032456),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,EHD1
plasma membrane bounded cell projection morphogenesis (GO:0120039),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,PAK1
regulation of release of sequestered calcium ion into cytosol (GO:0051279),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,GSTO1
regulation of telomere maintenance via telomerase (GO:0032210),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,PINX1
response to peptide hormone (GO:0043434),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,EIF2B5
signal transduction in response to DNA damage (GO:0042770),1/52,0.472243682,0.581399764,0,0,1.59001049,1.19292151,TIPRL
negative regulation of cysteine-type endopeptidase activity (GO:2000117),1/53,0.478699079,0.586967045,0,0,1.559354226,1.148749915,CD44
cardiac muscle tissue development (GO:0048738),1/53,0.478699079,0.586967045,0,0,1.559354226,1.148749915,SCN5A
positive regulation of chemokine production (GO:0032722),1/53,0.478699079,0.586967045,0,0,1.559354226,1.148749915,IL1B
heart morphogenesis (GO:0003007),1/53,0.478699079,0.586967045,0,0,1.559354226,1.148749915,FLRT2
positive regulation of phagocytosis (GO:0050766),1/53,0.478699079,0.586967045,0,0,1.559354226,1.148749915,IL1B
regulation of cell adhesion (GO:0030155),2/133,0.484218127,0.591441861,0,0,1.238092234,0.897889001,ARHGDIG;P4HB
regulation of focal adhesion assembly (GO:0051893),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,PEAK1
negative regulation of viral genome replication (GO:0045071),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,HMGA2
cytoplasmic microtubule organization (GO:0031122),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,WDR73
regulation of potassium ion transmembrane transport (GO:1901379),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,FLNA
positive regulation of leukocyte chemotaxis (GO:0002690),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,CSF1
striated muscle contraction (GO:0006941),1/54,0.485075835,0.591441861,0,0,1.529854802,1.106773519,SCN5A
negative regulation of multicellular organismal process (GO:0051241),3/214,0.48602738,0.592126455,0,0,1.153074669,0.831932211,IL1B;TIMP1;WDR77
positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731),2/134,0.488149484,0.594234897,0,0,1.228650138,0.881106296,HAX1;CD44
pyruvate metabolic process (GO:0006090),1/55,0.491374903,0.595772446,0,0,1.50144795,1.066850678,HK2
regulation of blood vessel endothelial cell migration (GO:0043535),1/55,0.491374903,0.595772446,0,0,1.50144795,1.066850678,NUS1
glycoprotein metabolic process (GO:0009100),1/55,0.491374903,0.595772446,0,0,1.50144795,1.066850678,FBXO17
positive regulation of response to DNA damage stimulus (GO:2001022),1/55,0.491374903,0.595772446,0,0,1.50144795,1.066850678,HMGA2
triglyceride metabolic process (GO:0006641),1/55,0.491374903,0.595772446,0,0,1.50144795,1.066850678,LPGAT1
DNA repair (GO:0006281),4/298,0.494142053,0.598649351,0,0,1.103287982,0.777743275,APEX1;POLD2;HMGA2;LIG3
protein localization to plasma membrane (GO:0072659),2/136,0.495955995,0.599962342,0,0,1.210188726,0.848666719,EHD1;FLNA
negative regulation of metabolic process (GO:0009892),1/56,0.497597226,0.599962342,0,0,1.474074074,1.028851098,IL1B
"nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:0000288)",1/56,0.497597226,0.599962342,0,0,1.474074074,1.028851098,EXOSC9
glycosaminoglycan catabolic process (GO:0006027),1/56,0.497597226,0.599962342,0,0,1.474074074,1.028851098,CD44
Rho protein signal transduction (GO:0007266),1/56,0.497597226,0.599962342,0,0,1.474074074,1.028851098,ARHGDIG
mitochondrial transport (GO:0006839),1/56,0.497597226,0.599962342,0,0,1.474074074,1.028851098,TIMM23
positive regulation of intracellular signal transduction (GO:1902533),7/546,0.500722563,0.603251468,0,0,1.053044002,0.728393799,HAX1;DHX33;IL1B;FLNA;PHB;MET;S100A8
carboxylic acid transport (GO:0046942),1/57,0.503743735,0.60497072,0,0,1.447677837,0.992654744,SLC16A6
positive regulation of interferon-gamma production (GO:0032729),1/57,0.503743735,0.60497072,0,0,1.447677837,0.992654744,IL1B
positive regulation of proteolysis (GO:0045862),1/57,0.503743735,0.60497072,0,0,1.447677837,0.992654744,IL1B
monocarboxylic acid transport (GO:0015718),1/57,0.503743735,0.60497072,0,0,1.447677837,0.992654744,SLC16A6
positive regulation of cell motility (GO:2000147),3/221,0.507428945,0.607933781,0,0,1.115649625,0.75685513,PAK1;CSF1;IL1B
negative regulation of hydrolase activity (GO:0051346),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,RRP1B
regulation of phagocytosis (GO:0050764),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,IL1B
fat cell differentiation (GO:0045444),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,HMGA2
positive regulation of protein binding (GO:0032092),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,NMD3
membrane lipid biosynthetic process (GO:0046467),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,PRKD3
mitochondrial respiratory chain complex I assembly (GO:0032981),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,NDUFAF4
muscle organ development (GO:0007517),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,ITGA7
NADH dehydrogenase complex assembly (GO:0010257),1/58,0.509815352,0.607933781,0,0,1.422207783,0.958150876,NDUFAF4
enzyme linked receptor protein signaling pathway (GO:0007167),2/140,0.511340753,0.608319172,0,0,1.174871242,0.788008553,CSF1;MET
transcription initiation from RNA polymerase II promoter (GO:0006367),2/140,0.511340753,0.608319172,0,0,1.174871242,0.788008553,GTF2F1;GTF2F2
protein localization to cell periphery (GO:1990778),2/140,0.511340753,0.608319172,0,0,1.174871242,0.788008553,EHD1;FLNA
negative regulation of autophagy (GO:0010507),1/59,0.515812983,0.611244425,0,0,1.397616007,0.925237192,MET
positive regulation of apoptotic signaling pathway (GO:2001235),1/59,0.515812983,0.611244425,0,0,1.397616007,0.925237192,S100A8
regulation of secretion by cell (GO:1903530),1/59,0.515812983,0.611244425,0,0,1.397616007,0.925237192,DNAJC1
response to reactive oxygen species (GO:0000302),1/59,0.515812983,0.611244425,0,0,1.397616007,0.925237192,CAMKK2
mitotic DNA damage checkpoint signaling (GO:0044773),1/59,0.515812983,0.611244425,0,0,1.397616007,0.925237192,HMGA2
regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122),3/224,0.516459323,0.611532958,0,0,1.100336081,0.727056692,TRAF3;IL1B;FLNA
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193),1/60,0.521737527,0.616340519,0,0,1.37385785,0.893819056,FLNA
cellular protein catabolic process (GO:0044257),1/60,0.521737527,0.616340519,0,0,1.37385785,0.893819056,CLPP
response to organic cyclic compound (GO:0014070),1/60,0.521737527,0.616340519,0,0,1.37385785,0.893819056,IL1B
negative regulation of DNA-binding transcription factor activity (GO:0043433),2/143,0.522676158,0.616969213,0,0,1.149698142,0.745916345,TRAF3;FLNA
negative regulation of response to stimulus (GO:0048585),1/61,0.527589872,0.621319958,0,0,1.350891632,0.863808816,HMGA2
positive regulation of interleukin-8 production (GO:0032757),1/61,0.527589872,0.621319958,0,0,1.350891632,0.863808816,IL1B
protein lipidation (GO:0006497),1/61,0.527589872,0.621319958,0,0,1.350891632,0.863808816,ZDHHC5
regulation of neurogenesis (GO:0050767),1/62,0.533370893,0.627154931,0,0,1.328678405,0.835125183,IL1B
glucose metabolic process (GO:0006006),1/62,0.533370893,0.627154931,0,0,1.328678405,0.835125183,ADPGK
apoptotic process (GO:0006915),3/231,0.53718103,0.631146133,0,0,1.066171653,0.662540525,IL1B;DDX41;HK2
negative regulation of endopeptidase activity (GO:0010951),1/63,0.539081456,0.631424113,0,0,1.307181734,0.807692685,TIMP1
negative regulation of peptidase activity (GO:0010466),1/63,0.539081456,0.631424113,0,0,1.307181734,0.807692685,TIMP1
cellular response to reactive oxygen species (GO:0034614),1/63,0.539081456,0.631424113,0,0,1.307181734,0.807692685,CAMKK2
positive regulation of Ras protein signal transduction (GO:0046579),1/63,0.539081456,0.631424113,0,0,1.307181734,0.807692685,LRRC59
positive regulation of intracellular protein transport (GO:0090316),2/148,0.541174292,0.63338672,0,0,1.110041888,0.681581133,IL1B;FLNA
regulation of extrinsic apoptotic signaling pathway (GO:2001236),1/64,0.544722416,0.635579268,0,0,1.286367496,0.781441165,PSME3
regulation of innate immune response (GO:0045088),1/64,0.544722416,0.635579268,0,0,1.286367496,0.781441165,POLR3G
regulation of transcription initiation from RNA polymerase II promoter (GO:0060260),1/64,0.544722416,0.635579268,0,0,1.286367496,0.781441165,MED4
protein catabolic process (GO:0030163),1/64,0.544722416,0.635579268,0,0,1.286367496,0.781441165,FBXO17
cellular response to organic cyclic compound (GO:0071407),2/150,0.548433869,0.639418289,0,0,1.09492964,0.657711725,RUVBL2;IL1B
regulation of RNA metabolic process (GO:0051252),1/65,0.550294619,0.641095343,0,0,1.266203704,0.756305337,RRP1B
negative regulation of gene expression (GO:0010629),4/322,0.555038279,0.645526188,0,0,1.018763103,0.599764377,AEBP2;SMYD5;PUS7;METTL16
ERBB signaling pathway (GO:0038127),1/66,0.555798899,0.645526188,0,0,1.246660336,0.732224381,PTPN12
positive regulation of cell death (GO:0010942),1/66,0.555798899,0.645526188,0,0,1.246660336,0.732224381,PHB
positive regulation of T cell proliferation (GO:0042102),1/66,0.555798899,0.645526188,0,0,1.246660336,0.732224381,IL1B
regulation of ERK1 and ERK2 cascade (GO:0070372),3/238,0.557391579,0.646881053,0,0,1.034042553,0.60438471,IL1B;PHB;CD44
regulation of gene expression (GO:0010468),13/1079,0.559060234,0.648321952,0,0,0.986696231,0.573761943,PRMT5;CSF1;HMGA1;HMGA2;RRP1B;PHB;MYBBP1A;TRAF3;IL1B;UBAP2;FAM98B;FAM98A;METTL16
anion transmembrane transport (GO:0098656),1/67,0.56123608,0.649852303,0,0,1.227709191,0.709141577,SFXN1
positive regulation of catabolic process (GO:0009896),1/67,0.56123608,0.649852303,0,0,1.227709191,0.709141577,IL1B
regulation of translational initiation (GO:0006446),1/68,0.566606977,0.65507189,0,0,1.209323752,0.687003977,EIF2B5
interferon-gamma-mediated signaling pathway (GO:0060333),1/68,0.566606977,0.65507189,0,0,1.209323752,0.687003977,CD44
cellular response to calcium ion (GO:0071277),1/69,0.571912395,0.65969834,0,0,1.191479061,0.665762105,SCN5A
cellular response to decreased oxygen levels (GO:0036294),1/69,0.571912395,0.65969834,0,0,1.191479061,0.665762105,P4HB
positive regulation of MAP kinase activity (GO:0043406),1/69,0.571912395,0.65969834,0,0,1.191479061,0.665762105,PAK1
mitotic spindle organization (GO:0007052),2/157,0.573205924,0.660688377,0,0,1.045107971,0.581613296,EML4;FLNA
wound healing (GO:0042060),1/70,0.577153129,0.66473327,0,0,1.174151607,0.645369682,PAK1
regulation of G1/S transition of mitotic cell cycle (GO:2000045),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,PSME3
cholesterol homeostasis (GO:0042632),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,EHD1
positive regulation of cellular protein localization (GO:1903829),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,RANGRF
regulation of TOR signaling (GO:0032006),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,ITFG2
histone acetylation (GO:0016573),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,RUVBL2
myeloid leukocyte differentiation (GO:0002573),1/71,0.582329965,0.667656259,0,0,1.157319224,0.625783385,CSF1
negative regulation of epithelial cell proliferation (GO:0050680),1/72,0.587443678,0.671490589,0,0,1.140960992,0.606962616,WDR77
cell junction organization (GO:0034330),1/72,0.587443678,0.671490589,0,0,1.140960992,0.606962616,FLNA
sterol homeostasis (GO:0055092),1/72,0.587443678,0.671490589,0,0,1.140960992,0.606962616,EHD1
positive regulation of secretion by cell (GO:1903532),1/72,0.587443678,0.671490589,0,0,1.140960992,0.606962616,IL1B
negative regulation of cell adhesion (GO:0007162),1/73,0.592495034,0.674724278,0,0,1.125057156,0.588869301,ARHGDIG
regulation of actin filament-based process (GO:0032970),1/73,0.592495034,0.674724278,0,0,1.125057156,0.588869301,PAK1
endoplasmic reticulum organization (GO:0007029),1/73,0.592495034,0.674724278,0,0,1.125057156,0.588869301,REEP3
regulation of Rho protein signal transduction (GO:0035023),1/73,0.592495034,0.674724278,0,0,1.125057156,0.588869301,MET
ubiquitin-dependent ERAD pathway (GO:0030433),1/73,0.592495034,0.674724278,0,0,1.125057156,0.588869301,FBXO17
organelle assembly (GO:0070925),5/425,0.594711716,0.675843453,0,0,0.963140068,0.500523187,EHD1;NSFL1C;FLNA;DHX29;EMC6
double-strand break repair (GO:0006302),2/164,0.596979417,0.675843453,0,0,0.999591878,0.515662106,PSMD14;LIG3
heart development (GO:0007507),2/164,0.596979417,0.675843453,0,0,0.999591878,0.515662106,FLRT2;MICAL2
proteolysis involved in cellular protein catabolic process (GO:0051603),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,CLPP
negative regulation of protein binding (GO:0032091),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,GTF2F1
cellular response to amino acid starvation (GO:0034198),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,ITFG2
regulation of peptide hormone secretion (GO:0090276),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,IL1B
sphingolipid biosynthetic process (GO:0030148),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,PRKD3
mitotic nuclear division (GO:0140014),1/74,0.597484792,0.675843453,0,0,1.109589041,0.571467703,FLNA
regulation of neuron projection development (GO:0010975),2/165,0.600293774,0.677882873,0,0,0.993408711,0.506972346,PAK1;NCS1
nucleic acid phosphodiester bond hydrolysis (GO:0090305),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,POLD2
response to amino acid starvation (GO:1990928),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,ITFG2
positive regulation of immune response (GO:0050778),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,POLR3G
positive regulation of lymphocyte proliferation (GO:0050671),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,IL1B
integrin-mediated signaling pathway (GO:0007229),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,NME2
positive regulation of T cell activation (GO:0050870),1/75,0.602413699,0.677882873,0,0,1.094538983,0.554724246,IL1B
regulation of nucleic acid-templated transcription (GO:1903506),5/430,0.605077196,0.679833943,0,0,0.951562885,0.478064462,PRMT5;MYBBP1A;HMGA1;HMGA2;PHB
regulation of epithelial to mesenchymal transition (GO:0010717),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,IL1B
cellular response to hormone stimulus (GO:0032870),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,PELP1
regulation of T cell proliferation (GO:0042129),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,IL1B
positive regulation of interleukin-6 production (GO:0032755),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,IL1B
RNA transport (GO:0050658),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,XPO5
protein import into nucleus (GO:0006606),1/76,0.607282494,0.679833943,0,0,1.079890261,0.538607364,TNPO3
negative regulation of developmental process (GO:0051093),1/77,0.612091908,0.68370531,0,0,1.065627031,0.523087358,WDR77
positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068),1/77,0.612091908,0.68370531,0,0,1.065627031,0.523087358,HAX1
positive regulation of protein modification by small protein conjugation or removal (GO:1903322),1/77,0.612091908,0.68370531,0,0,1.065627031,0.523087358,HSPBP1
neuron projection development (GO:0031175),2/171,0.619750207,0.69120208,0,0,0.957846349,0.458270833,EHD1;PAK1
nuclear-transcribed mRNA catabolic process (GO:0000956),2/171,0.619750207,0.69120208,0,0,0.957846349,0.458270833,ERI1;EXOSC9
regulation of cellular response to heat (GO:1900034),1/79,0.621535467,0.69120208,0,0,1.038197742,0.493727709,DNAJC2
negative regulation of NF-kappaB transcription factor activity (GO:0032088),1/79,0.621535467,0.69120208,0,0,1.038197742,0.493727709,TRAF3
positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436),1/79,0.621535467,0.69120208,0,0,1.038197742,0.493727709,HSPBP1
positive regulation of ubiquitin-dependent protein catabolic process (GO:2000060),1/79,0.621535467,0.69120208,0,0,1.038197742,0.493727709,HSPBP1
positive regulation of ERK1 and ERK2 cascade (GO:0070374),2/172,0.622921432,0.691932596,0,0,0.952163345,0.450692122,PHB;CD44
supramolecular fiber organization (GO:0097435),4/351,0.623103991,0.691932596,0,0,0.932228626,0.440983158,TPM4;ACTN1;WDR73;P4HB
positive regulation of cell adhesion (GO:0045785),1/80,0.626171029,0.694322587,0,0,1.025003907,0.479836858,P4HB
skin development (GO:0043588),1/80,0.626171029,0.694322587,0,0,1.025003907,0.479836858,MET
neuron differentiation (GO:0030182),2/174,0.629202749,0.696854851,0,0,0.940995579,0.435964889,MTPN;MET
ubiquitin-dependent protein catabolic process (GO:0006511),4/354,0.629761587,0.696854851,0,0,0.924095238,0.427314543,NSFL1C;PSMD14;PSME3;PSMD3
activation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0006919),1/81,0.630750043,0.696854851,0,0,1.012139918,0.466440252,S100A8
regulation of interleukin-8 production (GO:0032677),1/81,0.630750043,0.696854851,0,0,1.012139918,0.466440252,IL1B
positive regulation of cellular amide metabolic process (GO:0034250),1/81,0.630750043,0.696854851,0,0,1.012139918,0.466440252,GSAP
negative regulation of signal transduction (GO:0009968),3/267,0.635239734,0.699814739,0,0,0.919087137,0.417038378,IL1B;NFATC1;PTPN12
regulation of G protein-coupled receptor signaling pathway (GO:0008277),1/82,0.635273195,0.699814739,0,0,0.999593558,0.453515742,PHB
positive regulation of cytoskeleton organization (GO:0051495),1/82,0.635273195,0.699814739,0,0,0.999593558,0.453515742,HAX1
positive regulation of protein ubiquitination (GO:0031398),1/82,0.635273195,0.699814739,0,0,0.999593558,0.453515742,HSPBP1
glycerophospholipid biosynthetic process (GO:0046474),2/177,0.638472273,0.702188784,0,0,0.92472255,0.414901768,ARF3;TAMM41
regulation of defense response (GO:0031347),1/83,0.639741164,0.702188784,0,0,0.987353207,0.441042399,TRAF3
peptide metabolic process (GO:0006518),1/83,0.639741164,0.702188784,0,0,0.987353207,0.441042399,AEBP1
glycoprotein biosynthetic process (GO:0009101),1/83,0.639741164,0.702188784,0,0,0.987353207,0.441042399,NUS1
positive regulation of plasma membrane bounded cell projection assembly (GO:0120034),1/83,0.639741164,0.702188784,0,0,0.987353207,0.441042399,FAM98A
positive regulation of cell migration (GO:0030335),3/269,0.640244029,0.702232974,0,0,0.912083112,0.406703223,PAK1;CSF1;IL1B
regulation of cytokinesis (GO:0032465),1/84,0.644154622,0.704919256,0,0,0.975407804,0.429000432,CSPP1
nuclear export (GO:0051168),1/84,0.644154622,0.704919256,0,0,0.975407804,0.429000432,XPO5
spindle assembly (GO:0051225),1/84,0.644154622,0.704919256,0,0,0.975407804,0.429000432,FLNA
protein stabilization (GO:0050821),2/179,0.644550677,0.704919256,0,0,0.914180324,0.401509671,FLNA;PHB
B cell activation (GO:0042113),1/85,0.64851423,0.708233526,0,0,0.963746816,0.417371118,PHB
positive regulation of protein catabolic process (GO:0045732),1/85,0.64851423,0.708233526,0,0,0.963746816,0.417371118,IL1B
positive regulation of MAPK cascade (GO:0043410),3/274,0.652544236,0.709364162,0,0,0.89502534,0.382065149,DHX33;PHB;CD44
negative regulation of cellular amide metabolic process (GO:0034249),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,PUS7
regulation of interferon-gamma production (GO:0032649),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,IL1B
regulation of Ras protein signal transduction (GO:0046578),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,LRRC59
glucose homeostasis (GO:0042593),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,HK2
response to interleukin-1 (GO:0070555),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,IL1B
positive regulation of proteasomal protein catabolic process (GO:1901800),1/86,0.652820642,0.709364162,0,0,0.952360203,0.406136727,HSPBP1
ERAD pathway (GO:0036503),1/87,0.657074506,0.712965761,0,0,0.941238396,0.395280466,FBXO17
sodium ion transmembrane transport (GO:0035725),1/87,0.657074506,0.712965761,0,0,0.941238396,0.395280466,SCN5A
"retrograde transport, endosome to Golgi (GO:0042147)",1/88,0.661276459,0.717012617,0,0,0.930372262,0.384786415,SURF4
regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043281),1/89,0.665427133,0.719457541,0,0,0.919753086,0.374639474,CD44
collagen fibril organization (GO:0030199),1/89,0.665427133,0.719457541,0,0,0.919753086,0.374639474,P4HB
second-messenger-mediated signaling (GO:0019932),1/89,0.665427133,0.719457541,0,0,0.919753086,0.374639474,CAMKK2
protein import (GO:0017038),1/89,0.665427133,0.719457541,0,0,0.919753086,0.374639474,TNPO3
"regulation of mRNA splicing, via spliceosome (GO:0048024)",1/90,0.66952715,0.722346989,0,0,0.909372544,0.364825316,METTL16
positive regulation of autophagy (GO:0010508),1/90,0.66952715,0.722346989,0,0,0.909372544,0.364825316,CAMKK2
sodium ion transport (GO:0006814),1/90,0.66952715,0.722346989,0,0,0.909372544,0.364825316,SCN5A
regulation of actin cytoskeleton organization (GO:0032956),1/91,0.673577127,0.725684939,0,0,0.899222679,0.355330335,PAK1
positive regulation of transport (GO:0051050),1/91,0.673577127,0.725684939,0,0,0.899222679,0.355330335,IL1B
regulation of lipid metabolic process (GO:0019216),1/92,0.677577672,0.728960245,0,0,0.889295889,0.346141606,IL1B
T cell activation (GO:0042110),1/92,0.677577672,0.728960245,0,0,0.889295889,0.346141606,CD44
negative regulation of cell death (GO:0060548),1/94,0.685432861,0.736367363,0,0,0.870082747,0.328634365,CSF1
nucleosome organization (GO:0034728),1/94,0.685432861,0.736367363,0,0,0.870082747,0.328634365,HMGA1
protein localization to membrane (GO:0072657),2/195,0.690303823,0.741075816,0,0,0.837708217,0.310474314,EHD1;FLNA
protein maturation (GO:0051604),1/97,0.696859692,0.747057212,0,0,0.84276406,0.3043821,AEBP1
regulation of MAP kinase activity (GO:0043405),1/97,0.696859692,0.747057212,0,0,0.84276406,0.3043821,IL1B
negative regulation of intracellular signal transduction (GO:1902532),2/198,0.698324325,0.74809903,0,0,0.824759656,0.296147798,PLAUR;NOC2L
negative regulation of neuron death (GO:1901215),1/98,0.700576011,0.749453407,0,0,0.834033346,0.296792776,CSF1
regulation of neuron apoptotic process (GO:0043523),1/98,0.700576011,0.749453407,0,0,0.834033346,0.296792776,SIGMAR1
mRNA-containing ribonucleoprotein complex export from nucleus (GO:0071427),1/99,0.704246954,0.752849912,0,0,0.82548081,0.289435198,AGFG1
modification-dependent protein catabolic process (GO:0019941),2/201,0.706172672,0.754377281,0,0,0.812201503,0.282561242,PSMD14;PSMD3
positive regulation of translation (GO:0045727),1/100,0.707873073,0.755661972,0,0,0.817101052,0.282300632,EIF2B5
epithelial cell differentiation (GO:0030855),1/101,0.711454913,0.758951903,0,0,0.808888889,0.275380748,DNPH1
regulation of cell death (GO:0010941),1/102,0.714993013,0.760055598,0,0,0.800839343,0.268667591,PHB
calcium-mediated signaling (GO:0019722),1/102,0.714993013,0.760055598,0,0,0.800839343,0.268667591,CAMKK2
cell junction assembly (GO:0034329),1/102,0.714993013,0.760055598,0,0,0.800839343,0.268667591,FLNA
regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032434),1/102,0.714993013,0.760055598,0,0,0.800839343,0.268667591,HSPBP1
positive regulation of cellular protein metabolic process (GO:0032270),1/102,0.714993013,0.760055598,0,0,0.800839343,0.268667591,CSF1
regulation of inflammatory response (GO:0050727),2/206,0.718875902,0.763648439,0,0,0.792092043,0.261443075,IL1B;S100A8
regulation of insulin secretion (GO:0050796),1/104,0.721940114,0.765578476,0,0,0.785209157,0.25583142,IL1B
mRNA transport (GO:0051028),1/104,0.721940114,0.765578476,0,0,0.785209157,0.25583142,AGFG1
phosphorylation (GO:0016310),4/400,0.722205783,0.765578476,0,0,0.814814815,0.26517754,PAK1;PEAK1;NADK;CAMKK2
positive regulation of cellular metabolic process (GO:0031325),1/105,0.725350159,0.768375117,0,0,0.7776195,0.249694214,CSF1
protein processing (GO:0016485),1/106,0.728718554,0.770330616,0,0,0.770174407,0.243735318,AEBP1
cellular response to peptide hormone stimulus (GO:0071375),1/106,0.728718554,0.770330616,0,0,0.770174407,0.243735318,PRKAR2A
regulation of phosphatidylinositol 3-kinase signaling (GO:0014066),1/106,0.728718554,0.770330616,0,0,0.770174407,0.243735318,HAX1
response to calcium ion (GO:0051592),1/107,0.732045804,0.77241975,0,0,0.762869788,0.237948388,SCN5A
mRNA export from nucleus (GO:0006406),1/107,0.732045804,0.77241975,0,0,0.762869788,0.237948388,AGFG1
positive regulation of apoptotic process (GO:0043065),3/310,0.732221357,0.77241975,0,0,0.788611513,0.245788451,MYBBP1A;HMGA2;RRP1B
regulation of cell migration (GO:0030334),4/408,0.736409926,0.776298797,0,0,0.798349835,0.244269783,PAK1;CSF1;IL1B;FLNA
lipid transport (GO:0006869),1/109,0.738578869,0.777505355,0,0,0.748666362,0.226866411,NME4
modulation of chemical synaptic transmission (GO:0050804),1/109,0.738578869,0.777505355,0,0,0.748666362,0.226866411,IL1B
regulation of interleukin-6 production (GO:0032675),1/110,0.741785666,0.780340014,0,0,0.741760109,0.22155999,IL1B
regulation of protein serine/threonine kinase activity (GO:0071900),1/111,0.744953284,0.782587602,0,0,0.734979424,0.216402761,HMGA2
regulation of Wnt signaling pathway (GO:0030111),1/111,0.744953284,0.782587602,0,0,0.734979424,0.216402761,NFATC1
transcription by RNA polymerase II (GO:0006366),3/320,0.751631857,0.78905751,0,0,0.763341492,0.217940581,MED4;GTF2F1;GTF2F2
positive regulation of cellular component organization (GO:0051130),1/114,0.75422581,0.791233435,0,0,0.715357442,0.201776204,SURF4
sphingolipid metabolic process (GO:0006665),1/116,0.76022019,0.796971166,0,0,0.702844874,0.192682929,PRKD3
regulation of cellular response to stress (GO:0080135),1/118,0.766068952,0.801994944,0,0,0.690760086,0.184075887,DNAJC2
positive regulation of protein-containing complex assembly (GO:0031334),1/118,0.766068952,0.801994944,0,0,0.690760086,0.184075887,DHX33
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043280),1/119,0.76893983,0.804373171,0,0,0.684871312,0.179944839,S100A8
cilium organization (GO:0044782),2/228,0.769400424,0.804373171,0,0,0.714181233,0.187218138,EHD1;FLNA
cytoskeleton organization (GO:0007010),1/120,0.771775619,0.806301025,0,0,0.679081509,0.17592382,MICAL2
cellular response to interferon-gamma (GO:0071346),1/121,0.774576744,0.808670906,0,0,0.673388203,0.172009296,CD44
regulation of autophagy (GO:0010506),2/231,0.775643838,0.809228417,0,0,0.704716879,0.179041664,HAX1;MET
epithelium development (GO:0060429),1/122,0.777343629,0.8104448,0,0,0.667789001,0.168197869,DNPH1
regulation of anatomical structure morphogenesis (GO:0022603),1/123,0.780076689,0.812736043,0,0,0.662281589,0.164486272,PAK1
protein targeting (GO:0006605),1/125,0.785442981,0.81720524,0,0,0.651533254,0.157350111,TIMM23
cellular response to oxidative stress (GO:0034599),1/125,0.785442981,0.81720524,0,0,0.651533254,0.157350111,CAMKK2
negative regulation of cell growth (GO:0030308),1/126,0.78807702,0.817703976,0,0,0.646288066,0.153919612,PHB
negative regulation of growth (GO:0045926),1/126,0.78807702,0.817703976,0,0,0.646288066,0.153919612,PHB
circulatory system development (GO:0072359),1/126,0.78807702,0.817703976,0,0,0.646288066,0.153919612,MICAL2
phosphatidylinositol biosynthetic process (GO:0006661),1/126,0.78807702,0.817703976,0,0,0.646288066,0.153919612,ARF3
plasma membrane bounded cell projection organization (GO:0120036),1/128,0.793248871,0.821946612,0,0,0.636045494,0.147319758,EHD1
microtubule cytoskeleton organization involved in mitosis (GO:1902850),1/128,0.793248871,0.821946612,0,0,0.636045494,0.147319758,EML4
muscle contraction (GO:0006936),1/129,0.795787463,0.824014576,0,0,0.631044239,0.144145104,TPM4
regulation of response to external stimulus (GO:0032101),1/130,0.79829501,0.825484895,0,0,0.626120522,0.141050592,TRAF3
protein glycosylation (GO:0006486),1/130,0.79829501,0.825484895,0,0,0.626120522,0.141050592,NUS1
negative regulation of cellular macromolecule biosynthetic process (GO:2000113),5/547,0.800639703,0.826617618,0,0,0.741635659,0.164898418,MYBBP1A;HMGA1;HMGA2;PHB;PUS7
cellular response to metal ion (GO:0071248),1/131,0.800771891,0.826617618,0,0,0.621272555,0.13803381,SCN5A
anterograde trans-synaptic signaling (GO:0098916),2/244,0.801024056,0.826617618,0,0,0.666416228,0.14785397,PRKAR2A;CAMKK2
regulation of cell motility (GO:2000145),1/133,0.805635145,0.830811243,0,0,0.611796982,0.132224202,FLNA
negative regulation of inflammatory response to antigenic stimulus (GO:0002862),1/136,0.812709221,0.836969198,0,0,0.598110044,0.124037194,PRKAR2A
organic substance transport (GO:0071702),1/136,0.812709221,0.836969198,0,0,0.598110044,0.124037194,NME4
regulation of inflammatory response to antigenic stimulus (GO:0002861),1/137,0.815009793,0.8387694,0,0,0.593681917,0.121440694,PRKAR2A
protein dephosphorylation (GO:0006470),1/139,0.819526844,0.842846714,0,0,0.58501819,0.116435073,PTPN12
negative regulation of nucleic acid-templated transcription (GO:1903507),4/464,0.820843141,0.843628902,0,0,0.699130435,0.1380246,MYBBP1A;HMGA1;HMGA2;PHB
neuron projection morphogenesis (GO:0048812),1/140,0.821744006,0.843983357,0,0,0.580779821,0.114022388,PAK1
"negative regulation of transcription, DNA-templated (GO:0045892)",9/948,0.822525266,0.844214573,0,0,0.767466522,0.149944599,MYBBP1A;ORC2;SMYD2;HMGA1;FLNA;HMGA2;PHB;AEBP1;NOC2L
regulation of small GTPase mediated signal transduction (GO:0051056),1/141,0.823934039,0.844518482,0,0,0.576601999,0.111667512,ARHGDIG
positive regulation of cellular catabolic process (GO:0031331),1/141,0.823934039,0.844518482,0,0,0.576601999,0.111667512,IL1B
positive regulation of cell differentiation (GO:0045597),2/258,0.825487634,0.845024032,0,0,0.629519628,0.120729901,CSF1;IL1B
Ras protein signal transduction (GO:0007265),1/142,0.826097275,0.845024032,0,0,0.572483437,0.109368808,ARHGDIG
protein localization to organelle (GO:0033365),1/142,0.826097275,0.845024032,0,0,0.572483437,0.109368808,EHD1
receptor-mediated endocytosis (GO:0006898),1/143,0.828234039,0.846069496,0,0,0.568422883,0.107124697,M6PR
neuron development (GO:0048666),1/143,0.828234039,0.846069496,0,0,0.568422883,0.107124697,EHD1
negative regulation of cell migration (GO:0030336),1/144,0.830344654,0.847655135,0,0,0.56441912,0.104933652,TIMP1
protein transport (GO:0015031),3/369,0.830942987,0.84769587,0,0,0.659478947,0.122131606,EHD1;ARF3;SEC23IP
positive regulation of transferase activity (GO:0051347),1/148,0.838531945,0.854863326,0,0,0.548948798,0.096671311,MET
central nervous system development (GO:0007417),2/268,0.841276634,0.85708586,0,0,0.605542783,0.104658828,EIF2B5;SPATA5
brain development (GO:0007420),1/150,0.842476802,0.857158033,0,0,0.541525119,0.092822361,SPATA5
regulation of cytokine production (GO:0001817),1/150,0.842476802,0.857158033,0,0,0.541525119,0.092822361,TRAF3
negative regulation of transcription by RNA polymerase II (GO:0000122),6/684,0.844611735,0.858754597,0,0,0.709377556,0.119798435,ORC2;SMYD2;HMGA2;PHB;AEBP1;NOC2L
dephosphorylation (GO:0016311),1/153,0.848214829,0.86184077,0,0,0.530755902,0.087373747,PTPN12
plasma membrane bounded cell projection assembly (GO:0120031),2/278,0.855764533,0.868930141,0,0,0.58330339,0.090855347,EHD1;FLNA
skeletal system development (GO:0001501),1/158,0.857319282,0.869926919,0,0,0.51372179,0.079084835,CD44
positive regulation of programmed cell death (GO:0043068),2/286,0.866477605,0.878632601,0,0,0.566639506,0.081210217,HMGA2;RRP1B
regulation of transcription by RNA polymerase II (GO:0006357),22/2206,0.868861042,0.880461323,0,0,0.797330297,0.112082372,NME2;HMGA1;KTI12;HMGA2;NFATC1;RRP1B;PHB;AEBP1;NOC2L;MED4;GTF2F1;WDR77;FOSL1;COPS5;HAX1;AEBP2;APEX1;RUVBL2;ORC2;SMYD2;MET;PELP1
cellular protein-containing complex assembly (GO:0034622),1/168,0.873928532,0.885005678,0,0,0.482713585,0.065048879,CHCHD4
positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123),1/171,0.878524982,0.889067282,0,0,0.474122489,0.061404046,FLNA
cation transport (GO:0006812),1/174,0.882954509,0.89295466,0,0,0.465829349,0.057987182,SCN5A
defense response to bacterium (GO:0042742),1/176,0.885817782,0.895031511,0,0,0.460458554,0.055827843,S100A8
protein ubiquitination (GO:0016567),4/525,0.886187326,0.895031511,0,0,0.615323097,0.074347595,PSMD14;PSME3;PSMD3;FBXO17
negative regulation of immune response (GO:0050777),1/178,0.88861129,0.896882938,0,0,0.455209133,0.053758097,PRKAR2A
regulation of immune response (GO:0050776),1/179,0.889982413,0.897242896,0,0,0.452628659,0.052755489,TRAF3
chemical synaptic transmission (GO:0007268),2/306,0.890150067,0.897242896,0,0,0.528816877,0.06153589,PRKAR2A;CAMKK2
cilium assembly (GO:0060271),2/314,0.898483638,0.905041913,0,0,0.515045561,0.05513397,EHD1;FLNA
regulation of GTPase activity (GO:0043087),1/189,0.902802164,0.908788916,0,0,0.428333771,0.043797915,RRP1B
regulation of signal transduction (GO:0009966),1/198,0.913062251,0.91850795,0,0,0.408577218,0.037160596,TIMP1
regulation of macromolecule metabolic process (GO:0060255),1/200,0.915191548,0.920040245,0,0,0.404429555,0.035841313,UBAP2
positive regulation of multicellular organismal process (GO:0051240),2/345,0.925530369,0.929818068,0,0,0.467749319,0.03619834,IL1B;NME2
negative regulation of inflammatory response (GO:0050728),1/212,0.926919626,0.930597879,0,0,0.381194781,0.02892827,PRKAR2A
cellular response to DNA damage stimulus (GO:0006974),2/350,0.929200953,0.932271676,0,0,0.460910041,0.033844741,PAK1;APEX1
protein phosphorylation (GO:0006468),3/496,0.943485512,0.945978208,0,0,0.48638617,0.02829516,PAK1;PEAK1;CAMKK2
inorganic cation transmembrane transport (GO:0098662),1/274,0.966176953,0.968090175,0,0,0.293688479,0.010105316,SCN5A
nervous system development (GO:0007399),2/447,0.974138094,0.975423237,0,0,0.358640542,0.009397173,PRPS1;MET
innate immune response (GO:0045087),1/302,0.976134684,0.976778148,0,0,0.265985809,0.006424809,PHB
"regulation of transcription, DNA-templated (GO:0006355)",18/2244,0.982683266,0.982683266,0,0,0.627221334,0.010956567,PRMT5;NME2;HMGA1;KTI12;HMGA2;NFATC1;PHB;MED4;RRP8;WDR77;CAMKK2;FOSL1;DNAJC2;AEBP2;MYBBP1A;IL1B;RUVBL2;POLR3G
